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Brief summary - We established an explicit list of potentially clinically significant DDIs relevant to people 
aged ≥ 65 years, using a Delphi process with a European expert panel. The list can be used in clinical 
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Objectives: We aimed to establish an explicit list of potentially clinically significant DDIs in people aged ≥
65 years. 
Design: A preliminary list of potentially clinically significant DDIs was compiled, based on 154 DDIs 
identified from literature review. Subsequently, a two-round online Delphi survey was undertaken with a 
multidisciplinary expert panel. A consensus meeting and a final round were conducted to validate the 
final DDI list and the scope of information provided.   
Setting and Participants: 29 experts, including geriatricians and clinical pharmacists from eight European 
countries 
Measures: For each DDI, in the first two rounds, experts were asked to score the severity of potential 
harm on a five-point Likert scale. DDIs were directly included on the final list if the median score was 4 
(major) or 5 (catastrophic). DDIs with a median score of 3 (moderate) were discussed at a consensus 
meeting and included if ≥75% of participants voted for inclusion in the final round.  
Results: Consensus was achieved on 66 potentially clinically significant DDIs (28 had a median score of 
4/5 and 48 of 3 in the Delphi survey). Most concerned cardiovascular, antithrombotic, and central 
nervous system drugs. The final list includes information on the mechanism of interaction, harm, and 
management. Treatment modification is recommended for three-quarters of DDIs. 
Conclusion and implications: We validated a list of potentially clinically significant DDIs in older people, 
which can be used in clinical practice and education to support identification and management of DDIs 





Drug-drug interactions (DDIs) are common in older people and are associated with an increased risk of 
adverse drug events and hospitalisation.[1,2] Older adults are particularly susceptible to DDIs because of 
multimorbidity, polypharmacy, age-related changes in pharmacokinetics (i.e. the absorption, 
distribution, metabolism and elimination of drugs) and pharmacodynamics (i.e. the relation between the 
concentration of a drug and the response obtained) and treatment by multiple care providers.[2-4] 
Reported prevalence rates of DDIs in older people vary widely across studies (1.5% to 55%), reflecting 
variation in study population, setting, definitions and information sources used.[1,3,5,6] The severity of 
DDIs varies considerably and only a proportion of all DDIs leads to adverse clinical consequences.[3,5] 
These clinically significant DDIs are particularly important to detect, as they are a preventable cause of 
morbidity and mortality.[3,6,7]  
It has been proposed that consensus is needed for identifying clinically significant DDIs in order to 
generate comparable results across studies.[5] Moreover, clinically significant DDIs have been recently 
selected as one of the core outcomes for clinical trials of medicines optimisation in older people.[8,9] 
While a number of explicit tools to screen for potentially inappropriate prescribing (including DDIs) in 
older people are available,[10] no list of potentially clinically significant DDIs validated specifically for use 
in older people exists. We aimed to establish an explicit list of potentially clinically significant DDIs 





A list of potentially clinically significant DDIs in older people was developed in four steps: a literature 
review to compile a preliminary list of DDIs for inclusion in the Delphi survey; a two-round Delphi survey, 
followed by a consensus meeting and final round; compiling the final list (Appendix 1).  
1. Literature review  
A systematic overview of inappropriate prescribing assessment tools (i.e. their first table that identified 
tools with DDI items[10])- and the authors’ knowledge of the published literature base served as a starting 
point to identify explicit DDI lists in older people. Furthermore, we searched PubMed using the terms 
‘Drug Interactions’ and ‘Potentially Inappropriate Medication List’. Articles published between January 
1990 and March 2018 were eligible if they contained a list of DDIs in older patients. Other types of 
studies (e.g. case reports, studies evaluating a specific DDI) were excluded. We performed a manual 
search from the reference list of included articles. Only the latest available version of the DDI list was 
included.  
The research team reviewed the DDIs retrieved in the lists and made the following modifications: DDIs 
reported by only one list and not classified as a major interaction by recognised DDI sources 
(Micromedex and/or UpToDate) were excluded; some DDIs were merged (i.e. when there was overlap); 
DDIs with direct oral anticoagulants (DOACs) were not reported in any of the DDI lists retrieved from the 
literature but were added based on data from review papers [11,12] and from experimental and 
pharmacoepidemiologic studies (full list of references available upon request) . 
2. Two-round Delphi survey  
Experts from nine centres in eight countries (Belgium, Iceland, Ireland, Italy, The Netherlands, Spain, 
Switzerland and United Kingdom) were invited to participate in the survey by e-mail. Experts included 




prescribing and (b) involvement in either the SENATOR or OPERAM trials evaluating medicines 
optimisation in older people.[13,14] We aimed for 4 participants, with a minimum of one physician and one 
pharmacist, per country. Experts who did not take part in one Round were excluded for the next Round. 
A modified two-round Delphi survey was conducted by e-mail between June and July 2018. In Round 1, 
panellists were asked to score, for each DDI from the preliminary list, the severity of potential harm 
(defined as the impact of the DDI) on a five-point Likert scale (1=insignificant, no risk of patient injury or 
harm and no intervention required; 2=minor, minor injury or illness requiring minor intervention; 
3=moderate, moderate injury requiring intervention; 4=major, major injury requiring intervention; 
5=catastrophic, leading to death, multiple permanent injuries, or irreversible health effects[15]). Each DDI 
included a brief explanation concerning the type of interaction (pharmacodynamics [i.e. drugs with 
additive or opposing effects] or pharmacokinetic [i.e. one drug affects the absorption, distribution, 
metabolism or elimination of another drug]), mechanism, potential harm and the number of existing lists 
mentioning the particular DDI. A box was provided for each DDI to allow for comments. Panellists could 
also propose additional DDIs. Panellists were instructed to score the severity of potential harm, assuming 
that the drug was prescribed at a normal dose, the prescriber had not taken into account a possible DDI 
and did not put in place preventive interventions. Panellists were also instructed to avoid consideration 
of the frequency of use of the drug. When several adverse consequences for a certain DDI were listed as 
‘potential harm’, panellists were asked to score the severity for the most serious consequence. 
For each DDI, consensus measurement was based on the median score and the interquartile range, as 
suggested and used in previous research.[16,17] The cut-off values for consensus measurement were pre-
defined: DDIs with a median score of ≥4 and P25 ≥3 were directly  included in the final list of DDIs; DDIs 
with a median score of <3 were directly excluded;  DDIs with a median score of 3 were neither included 




In Round 2, panellists were asked to re-evaluate the DDIs with a median score of 3 from Round 1 on the 
five-point Likert scale. Panellists were provided with a reminder of their own responses from Round 1, 
the median group score and the interquartile range. Furthermore, panellists were asked to evaluate the 
DDIs that were newly proposed in Round 1 and space for comments and proposal of additional DDIs was 
provided. After Round 2, the DDIs that did not meet the cut-off values for direct inclusion/exclusion were 
discussed in a consensus meeting. 
After each round, participants’ comments were scrutinised and considered carefully prior to preparing 
the next step of the study. 
3. Consensus meeting and final round 
A consensus meeting was performed by teleconference. The results of the Delphi survey were 
presented. The aim of the consensus meeting was to discuss how to address the set of DDIs with a 
median score of 3 from Round 2, to agree on the possibility to merge or split-up certain DDIs (based on 
comments made by panellists or by the research team) and to decide on the information to be provided 
in the final DDI list. To maximise feasibility, we aimed to have one participant per country, and both 
professions (pharmacists and physicians) represented. A final round was then conducted with all 
participants from Round 2. A summary of the results from Round 2 and of the consensus meeting were 
provided. Each participant was asked to specify whether or not, for each DDI that had a median score of 3 
at round 2, this DDI should be included in the final list. A DDI was included if ≥75% of participants rated it 
YES in this final round. 
4. Compiling the final list of DDIs  
To compile a DDI list that can be applied in practice, the mechanism, the potential harm and 




and Drugs.com were used as drug interaction compendia. The final table was double-checked by 
members of the Delphi panel for accuracy.  
RESULTS 
An overview of the DDIs evaluated and included at each step of the process is available in Appendix 1. 
1. Literature review to compile a preliminary list of DDIs 
Eleven explicit lists including 154 DDIs were retrieved from the literature (Table 1).  
Following review by the research team, 49 DDIs were removed (not classified as major by DDI sources), 
50 DDIs were modified (i.e. merged) and two DDIs with DOACs were added, resulting in a total of 74 DDIs 
for inclusion in the Delphi survey.  
2. Two-round delphi survey 
Of the 35 healthcare professionals who were invited, 29 (82.9%) and 28 (80.0%) completed Round 1 and 
2, respectively. Delphi panellists included 12 geriatricians, 15 pharmacists and two internal medicine 
specialists from eight European countries. Fourteen, seven and eight panellists had >15 years, 6-15 years 
and 0-5 years of practice experience, respectively.   
Out of the 74 DDIs presented in Round 1, there was consensus to include 23 DDIs in the final DDI list and 
to exclude six DDIs. Forty-five DDIs had a median score of 3 and were re-evaluated in Round 2. Eight 
additional DDIs were suggested by panellists. Out of the 53 DDIs presented in Round 2, there was 
consensus to include five DDIs and to exclude one DDI. Forty-seven DDIs with a median score of 3 were 





3. Consensus meeting and final round 
Eight experts (5 geriatricians, 2 pharmacists and 1 internal medicine physician from eight countries) took 
part in the consensus meeting. They recommended that the DDIs with a median score of 3 should be 
included on the final list. Hence all DDIs included on the final list require an intervention (median score ≥
3). Twenty-four Delphi participants completed the final round. Consensus was not achieved (i.e. <75% of 
participants rated YES) for 3 DDIs (Appendix 3). 
The list of excluded DDIs is presented in Appendix 4.  
4. Compiling the final list of DDIs  
After merging or splitting-up certain DDI pairs (in case of overlap or differences in the type or 
management of DDI, based on suggestions by panellists and research team members), the final list 
comprises 66 potentially clinically significant DDIs in older people, including the type and mechanism of 
the interaction, potential harm and management (Table 2 and Appendix 5). The list includes 30 
pharmacokinetic DDIs, 24 pharmacodynamic DDIs, 9 DDIs that are both pharmacokinetic and 
pharmacodynamic in nature and 3 DDIs for which the mechanism is not fully understood. Most DDIs 
concern antithrombotic agents, cardiovascular system drugs, central nervous system drugs and drugs 
with a narrow therapeutic index (e.g. digoxin). In terms of DDI management, treatment modification (i.e. 
dose reduction, discontinuation, substitution, adding a protective drug) is recommended for almost 
three-quarters of DDIs (48/66) and monitoring (e.g. electrolytes, blood pressure) is recommended for 
one quarter (18/66). Appendix 6 includes two summary tables of DDIs, per medication class and per type 






To our knowledge, this is the first list of potentially clinically significant DDIs in patients aged ≥65 years 
validated using an international Delphi panel. Consensus was achieved on 66 DDIs. The DDI list provides 
detailed information on the mechanism, potential harm and management of DDIs. Similar to explicit 
tools to detect potentially inappropriate prescribing in older people, the DDI list can be used to educate 
and assist healthcare professionals to detect potentially clinically significant DDIs. The DDI list could also 
be used to determine the prevalence of DDIs in epidemiological and intervention studies, as requested 
by recent core outcome sets.[8,9]  
Most DDIs included in the DDI list concern antithrombotic agents, cardiovascular system drugs and 
central nervous system drugs causing severe potential harm such as bleeding, electrolyte disorders, 
serotonin syndrome etc. Although most of the medications involved are not considered potentially 
inappropriate when taken in isolation, DDIs with these medication classes have been shown to be among 
the most prevalent DDIs in both hospitalised and community-dwelling older people.[6,18,19] Hanlon et al. 
showed that 24%, 9% and 2% of older adults had a potential DDI involving cardiovascular medications, 
antithrombotic agents and central nervous system drugs, respectively.[18] Becker et al. found that most 
admissions related to DDIs were bleeding events (mostly involving NSAIDs, anticoagulants and 
corticosteroids), hyper- or hypotension, cardiac rhythm disturbances (mostly involving diuretics, 
glycosides, calcium channel blockers).[5] Juurlink et al. demonstrated that patients admitted with digoxin 
toxicity were 12 times more likely to have been co-prescribed clarithromycin and that patients on ACE-
inhibitors admitted with hyperkalaemia were 20 times more likely to have been prescribed a potassium-
sparing diuretic.[7] Our DDI list encompasses these situations and also includes some DDIs that either 
involve medications taken mostly by older people (e.g. DDI-57) or that might lead to geriatric syndromes 




disopyramide, theophylline, cimetidine). We asked panellists to avoid taking into account in their ratings 
the frequency of use of the drug in practice. As these drugs are still available on the international market 
and clinicians may be less aware of these DDIs because of infrequent use, we believe it is relevant to 
have included them.   
Two lists of potentially serious DDIs in older people have been previously described, yet neither of them 
has been fully validated.[18,20] Furthermore, nine explicit tools designed to screen for inappropriate 
prescribing were identified from our literature review.[16,21-28] However, usually only a small proportion of 
the criteria is dedicated to DDIs and most lack information on the management of DDIs.[16,21-28] 
Incorporation of information on the mechanism, potential harm and the management of DDIs, enhances 
the clinical relevance of our tool. The DDI list is not intended to identify all potential DDIs in a given 
patient, but rather to call attention to drug combinations that are commonly problematic in older adults. 
Its use is different but complementary to that of specific DDI resources, which can be used for fully 
detailed information on the evidence and management of these DDIs, and to identify additional 
potential DDIs in individual patients. The explicit nature of the DDI list allows for easy implementation in 
clinical decision support systems and can be used to support communication with prescribers at 
dispensing, but it does not replace the more comprehensive electronic systems detecting an unrestricted 
number of DDIs. Table 3 lists six key principles to guide optimal use of the DDI list by clinicians.  
Future perspectives include determining the prevalence of DDIs in different populations, and 
investigating the association with clinical outcomes such as drug-related hospitalisations. An algorithm 
based on the ATC codes of the 66 DDIs is available via https://github.com/agapiospanos/DDI. 
 




The DDI list was developed combining evidence from the literature and the Delphi method. We 
scrutinised drug interaction compendia to expand the list of DDIs with practical information on 
management of the DDIs. A major limitation of this work is that the literature review was not systematic, 
ended at March 2018, used only PubMed to identify explicit DDI lists for older people and did not include 
a grading of the evidence base behind each DDI. Explicit DDI lists  developed for the adult population in 
general were not considered.[29] The 2019 version of the AGS Beers criteria was published after our 
literature review and lists 17 potentially clinically important DDIs that should be avoided in older 
adults.[30] Thirteen are part of our final DDI list. Two DDIs are not included (i.e., phenytoin-TMP/SMX and 
peripheral -1 blockers-loop diuretics), and a final two are partially covered (i.e., opioids-
benzodiazepines and opioids-gabapentin, pregabalin). These should be considered for inclusion in a 
future version, together with individual DDIs examined in pharmacoepidemiologic studies. 
Selection of participants is the most important step of a Delphi study.[17] Hence, inclusion of a large 
international, multidisciplinary expert panel is a strength of our study. Some Delphi panellists reported 
having difficulties with rating the clinical relevance of a DDI without taking into account the likelihood of 
the DDI or preventive interventions, as requested in the survey instructions. There might have been 
different ways of scoring the DDIs in the Delphi survey. However, it was a deliberate choice to only score 
the severity of the DDI since our primary aim was to establish a list of clinically significant DDIs, 
regardless of the likelihood of the interaction.  
Screening for all aspects of inappropriate prescribing as well as implicit patient-centred approaches 
remain key to medicines optimisation in older people.[32]  
CONCLUSIONS AND IMPLICATIONS 
We developed a tool for detection of potentially clinically significant DDIs in older people, based on 




panel. The 66-item DDI list can be used to assist healthcare professionals to detect potentially clinically 
significant DDIs in older people or to assess the prevalence of these DDIs in epidemiological and 
intervention studies. Evaluation of the performance of the DDI list in terms of its association with clinical 
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Table 1. Lists of DDIs identified from the literature review 




Existing list of DDIs 
Hanlon et al. 2017 [18] 31 Literature search Community 
Mimica Matanovic et al 2012. [20] 70 Literature search Not specified 
Explicit tools to detect inappropriate prescribing in older people and including DDIs 
The AGS 2015 Beers criteria [21] 13 Delphi method Not specified 




STOPP v2 (2015) [16] 8 Delphi method Not specified 
Laroche criteria (2007) [23] 3 Delphi method Not specified 
NORGEP (2009) [24] 15 Delphi method Community 
NORGEP-NH (2015) [25] 15 Delphi method Long-term care 
Rancourt (2004) [27] 35 Delphi method Long-term care 
Winit-Watjana (2008) [26] 12 Delphi method Not specified 
Top 10 Particularly dangerous drug interactions 
(2018) [28] 
10 Expert panel  Long-term care 






Table 2. Final list of potentially clinically significant drug-drug interactions in older people (n=66)* 
DDI-
number 
Drug-drug interaction pairs 
Type of 
DDI† 
Potential harm Management 
DDI-1 digoxin + amiodarone PK + PD 
Digoxin toxicity, that 
may lead to 
potentially fatal 
cardiac arrhythmia 
- Monitor serum digoxin levels closely and adjust dosage accordingly 
- Advise patients to promptly report any signs of digoxin toxicity such as nausea, vomiting, 
anorexia, visual disturbances, slow pulse/bradycardia, or irregular heartbeat/arrhythmia  
- DDI-1: Reduce the digoxin dosage by one-third to one-half  
- DDI-2: Reduce the digoxin dosage by one-third to one-half 
- DDI-4: Reduce the digoxin dosage by one-half 
- DDI-5: Substitute with non-macrolide antibiotic or reduce digoxin dosage by one-third to one-
half 
- DDI-6: Closely monitor serum levels of digoxin, potassium and magnesium 
DDI-2 digoxin + verapamil or diltiazem PK + PD 
DDI-3 digoxin + propafenone Unknown 
DDI-4 digoxin + quinidine PK 
DDI-5 
digoxin + some macrolides (i.e. 
erythromycin or clarithromycin or 
azithromycin or roxithromycin or 
telithromycin) 
PK 
DDI-6 digoxin + thiazide or loop diuretic PD 
DDI-7 vitamin K antagonist + a fibrate PK + PD 
Bleeding 
- Monitor the INR closely and adjust the vitamin K antagonist dosage accordingly 
- Advise patients to report any signs of excessive anticoagulation such as unusual or prolonged 
bleeding, bruising, vomiting, change in stool or urine colour, headache, dizziness or weakness 
- DDI-7: Reduce the vitamin K antagonist dosage by one-third to one-half 
- DDI-8: Substitute with a non-interacting gastroprotective drug (e.g. PPI like pantoprazole or 
another H2 antagonist) 
- DDI-10: Reduce the vitamin K antagonist dosage by one-quarter to one-half  
DDI-8 vitamin K antagonist + cimetidine PK 
DDI-9 vitamin K antagonist + metronidazole PK 
DDI-10 vitamin K antagonist + amiodarone PK 
DDI-11 
oral anticoagulant (i.e. vitamin K 
antagonist or factor Xa inhibitor or direct 








- Advise patients to promptly report any signs of excessive anticoagulation such as unusual or 
prolonged bleeding, bruising, vomiting, change in stool or urine colour, headache, dizziness or 
weakness  
- DDI-11: Consider the addition of a PPI or H2 antagonist during treatment with NSAID 
DDI-12 




vitamin K antagonist + 
trimethoprim/sulfamethoxazole 
PK + PD 
Bleeding 
- Monitor the INR closely and adjust the vitamin K antagonist dosage accordingly 
- Advise patients to promptly report any signs of excessive anticoagulation such as unusual or 
prolonged bleeding, bruising, vomiting, change in stool or urine colour, headache, dizziness or 
weakness 
- DDI-13: Substitute with another antibiotic 
DDI-14 vitamin K antagonist + a quinolone Unknown 
DDI-15 vitamin K antagonist + a macrolide PK + PD 
DDI-16 
dabigatran + a P-gp inhibitor 
(ketoconazole, itraconazole, verapamil, 
quinidine,  amiodarone, dronedarone, 




- Advise patients to promptly report any signs of excessive anticoagulation such as unusual or 
prolonged bleeding, bruising, vomiting, change in stool or urine colour, headache, dizziness or 
weakness  
- Specific recommendations for management may differ depending on: presence of risk factors 
(including renal failure), indication, interacting drug. Refer to appropriate literature and SmPC. 
- DDI-16: Not recommended with ketoconazole, itraconazole, ciclosporin, dronedarone, 
ritonavir. For other interacting drugs, use with caution and/or reduce dosage. 
- DDI-17: Reduce dosage or use with caution. 
- DDI-18: Not recommended with azoles, ritonavir, dronedarone. For other interacting drugs, 
DDI-17 




rivaroxaban + a P-gp inhibitor or a CYP3A4-





voriconazole, posaconazole, fluconazole, 
diltiazem, verapamil, quinidine, 
dronedarone, amiodarone, ciclosporin, , 
clarithromycin, erythromycin, ritonavir) 
avoid use or use with caution 
- DDI-19: Not recommended with azoles, ritonavir. For other interacting drugs, avoid use, 
reduce dosage and/or use with caution 
DDI-19 














effect with aspirin 
- Consider the addition of gastroprotective drugs (e.g. PPI) 
- Advise patients to promptly report any signs of ulceration and bleeding such as abdominal pain, 
bloating, sudden dizziness or light-headedness, nausea, vomiting, hematemesis, anorexia, and 
melena 
- In order to preserve the cardioprotective effect of low-dose aspirin, administer the latter at 
least 2 hours before or at least 8h after NSAID intake 
DDI-21 
concomitant use of ≥ 2 potassium-sparing 
drugs (i.e. amiloride, triamterene, 
eplerenone, spironolactone, ACE 




- Closely monitor patients for serum potassium levels and renal function 
- Educate patients about the potential danger of excessive potassium in the diet and advise them 
to promptly report any signs of hyperkalaemia such as nausea, vomiting, weakness, listlessness, 
tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat  
- DDI-21: Extra caution is required in patients with moderate renal impairment, diabetes, severe 
or worsening heart failure, dehydration, or concomitant therapy with other agents that 
increase serum potassium such as beta-blockers, ciclosporine, heparin, tacrolimus, and 
trimethoprim. Avoid concurrent use in patients with severe renal impairment (CrCl < 30 
ml/min) 
DDI-22 
ACE inhibitor or ARB or a potassium-
sparing diuretic + a potassium supplement 
PD 
DDI-23 ACE inhibitor or ARB + an oral NSAID  PD 




pressure control   
- Keep the use of NSAIDs to a minimum in patients on antihypertensives, especially in those with 
blood pressures that are relatively high, as well as in those with high salt intake 
- Monitor patient for altered blood pressure control and for renal function 
- Ensure adequate hydration, avoiding dehydration or fluid overload 
DDI-24 diuretic + oral NSAID PD 







- Keep the use of NSAID to a minimum in patients taking diuretics, especially in those with blood 
pressures that are relatively high, as well as in those with high salt intake or with congestive 
heart failure 
- Monitor patients for signs of worsening renal function and assure diuretic efficacy, including 
appropriate effects on blood pressure 
- Ensure adequate hydration, avoiding dehydration or fluid overload 
DDI-25 statin + gemfibrozil PK 
Severe myopathy and 
rhabdomyolysis which 
may lead to acute 
renal failure and 
death 
- Discontinue statin therapy if creatine kinase is markedly elevated in the absence of strenuous 
exercise or if myopathy is otherwise suspected or diagnosed 
- Advise patients to promptly report any unexplained muscle pain, tenderness or weakness, 
particularly if accompanied by fever, malaise, dark-coloured urine 
- DDI-25: Contraindicated in a number of conditions considered to be risk factors for myopathy 
DDI-26 
atorvastatin or simvastatin or lovastatin + 





DDI-27 simvastatin + amlodipine PK 
(i.e. renal impairment, hypothyroidism). Reduce the statin dosage to the lowest effective dose 
and consider using a fibrate other than gemfibrozil. If maintained, gemfibrozil dosage should 
not exceed 10mg daily 
- DDI-26,27, 28: Consider safer alternatives not metabolized by CYP3A4 (e.g. fluvastatin, 
pravastatin or rosuvastatin).  
- DDI-26,27, 28, 29: Reduce the dosage of involved statins to the lowest effective dose –do not 
exceed 20mg simvastatin and 40mg lovastatin daily 
- DDI-29: Substitute with a non-interacting antibiotic or temporarily withdraw the statin as long 
as macrolide antibiotics are required, except if benefits outweigh risks 
DDI-28 




atorvastatin or simvastatin or lovastatin + 
some macrolides (i.e. erythromycin or 




calcium channel blocker + a CYP3A4 
inhibitor ‡  
PK 
Increased effects of 
calcium channel 
blockers  
- Monitor patients for cardiotoxicity (e.g. QT prolongation, torsade de pointes, bradycardia, 
congestive heart failure) 
- Advise patients to promptly report any increased effects of calcium channels blockers such as 
headache, flushing, excessive hypotension, reflex tachycardia, oedema, difficulties breathing, 
chest pain or tightness  
DDI-31 
disopyramide + some macrolides (i.e. 
erythromycin, clarithromycin 
telithromycin) 
PK + PD 
Hypoglycaemic coma, 
QT prolongation, 
torsade de pointes, 
heart block and 
ventricular fibrillation 
- Avoid concurrent use except if benefits outweigh risks 
- Substitute with non-macrolide antibiotic 
- Closely monitor patients for cardiotoxicity 
- Advise patients to promptly report any symptoms that could indicate the occurrence of torsade 
de pointes such as dizziness, light-headedness, fainting, palpitations, irregular heartbeat, 
shortness of breath, or syncope 









asystole, sinus arrest, 
heart block 
- Avoid concurrent use, particularly in patients predisposed to heart failure 
- Closely monitor patient hemodynamic response and tolerance and adjust the dosage of one or 
both agents accordingly 
- Advise patients to promptly report any symptoms including fatigue, headache, fainting, 
swelling of the extremities, weight gain, shortness of breath, chest pain, increased or decreased 
heartbeat, or irregular heartbeat 
DDI-33 procainamide + amiodarone PD 
(Exacerbation of pre-
existing) arrhythmias 
and QT prolongation 
- Avoid concurrent use except for patients with life-threatening ventricular arrhythmias who are 
incompletely responsive to a single agent or to amiodarone alone 
- Reduce the dosage of both agents by one-third to one-half 
- Monitor patients for conduction disturbances and exacerbation of tachyarrhythmia 
- Advise patients to promptly report any symptoms that could indicate the occurrence of torsade 
de pointes such as dizziness, light-headedness, fainting, palpitations, irregular heartbeat, 
shortness of breath, or syncope. 
DDI-34 procainamide + trimethoprim PK 
Cardiac adverse 
effects including QT 
prolongation, torsade 
de pointes, cardiac 
arrest 
- Reduce the procainamide dosage. Monitor serum procainamide levels as well as patient 
response and adjust the procainamide dosage accordingly 
- Patients should be advised to promptly report any signs of procainamide toxicity including 




DDI-35 furosemide + etacrynic acid PD 
Ototoxicity with risk of 
tinnitus, reversible or 
irreversible hearing 
impairment, deafness 
- Avoid concurrent use 
DDI-36 
concomitant use of  ≥ 3 centrally-acting 
drugs (i.e. opiates or antipsychotics or 
benzodiazepines/z-drugs or barbiturates or  
antiepileptics or antidepressants) 
PD 
Increased risk of falls 
and fracture, impaired 
cognition 
- Minimise the number of CNS agents 
- Limit the dosage and duration of each drug to the minimum possible while achieving the 
desired clinical effect 
- Closely monitor patients for adverse effects 
DDI-37 
alprazolam or diazepam or midazolam or 
triazolam or zolpidem or zopiclone + a 





- Consider benzodiazepine/Z-drug dosage reduction 
- Advise patients to promptly report any symptoms of nausea, vomiting, diarrhoea, confusion, 
daytime sedation, dizziness or unconsciousness 
DDI-38 






PD + PK 






- Closely monitor for symptoms of the serotonin syndrome such as hypertension, tachycardia, 
hyperthermia, myoclonus, mental status changes, particularly when initiating or increasing 
dosages of these agents. Consider potential risk even when administering serotonergic agents 
sequentially, as some of them may demonstrate prolonged elimination half-life (e.g. fluoxetine)  
- With tramadol, use with caution regarding increased risk of seizure and monitor patient’s 
therapeutic response  
- When discontinuing a serotonergic CYP2D6 inhibitor in a patient receiving tramadol therapy, 
consider a tramadol dose reduction and monitor for signs of respiratory depression or sedation 




- Substitute with alternatives to NSAIDs (e.g. paracetamol) or less gastrotoxic NSAIDs (e.g. 
ibuprofen) 
- Consider the addition of gastroprotective drugs (e.g. PPI, H2 antagonists) 
- Advise patients to promptly report any signs of excessive anticoagulation such as unusual or 
prolonged bleeding, bruising, vomiting, change in stool or urine colour, headache, dizziness or 
weakness  
DDI-40 fluoxetine + tricyclic antidepressant PD + PK 




cardiac arrhythmias  
- Consider tricyclic antidepressant dosage reduction and serum level monitoring, even several 
weeks after fluoxetine discontinuation  
- Closely monitor patients for signs of tricyclic antidepressants toxicity (e.g.  cardiac arrhythmias, 
sedation, dry mouth, blurred vision, constipation, urinary retention) and/or excessive 
serotonergic activity (e.g. CNS irritability, altered consciousness, confusion, myoclonus, ataxia, 
abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and 
tachycardia)  
- If serotonin syndrome occurs, immediately discontinue fluoxetine and tricyclic antidepressants  
- If ventricular arrhythmias develop, consider fluoxetine discontinuation and cardiac evaluation  




- Extra caution is advised in a number of conditions including advanced age, impaired renal 
function, decreased sodium intake, volume depletion, renal artery stenosis, and heart failure as 
these increase the risk of toxicity. 
- Reduce the lithium dosage, titrate slowly and frequently monitor serum concentrations  
- Closely monitor patients for signs of lithium toxicity including drowsiness, dizziness, confusion, 
weakness, ataxia, tremor, tinnitus, blurred vision, nystagmus, vomiting, diarrhoea, thirst, 
diabetes insipidus (polyuria, polydipsia), seizure and ECG changes  
- Advise patients to promptly report any signs of lithium toxicity (listed above)  
DDI-42 lithium + diuretic PK 





MAO inhibitor (i.e. phenelzine, 
moclobemide, rasagiline, safinamide, 
selegiline, linezolid) + sympathomimetic 
PD 
Hypertensive crisis 
- DDI-44: Concurrent use is contraindicated. Wait at least 14 days after MAO inhibitor 
discontinuation before starting sympathomimetic use 
- DDI-45: Avoid concurrent use even if carbidopa or benserazide are given in combination with 
levodopa. Wait two to three weeks after MAO-A inhibitor discontinuation before starting 
levodopa treatment 
DDI-45 
MAO-A inhibitor  (i.e. moclobemide) or 
non-selective MAO inhibitor (i.e. 
phenelzine or linezolid) + levodopa 
PD 
DDI-46 
MAO inhibitor (i.e. phenelzine, 
moclobemide, rasagiline, safinamide, 
selegiline, linezolid) + some opioids (i.e. 
meperidine or fentanyl) 
PD 





- Concurrent use is contraindicated or not recommended  
- Wait at least 14 days after MAO inhibitor discontinuation before starting an opioid 
DDI-47 
MAO inhibitor (i.e. phenelzine, 
moclobemide, rasagiline, safinamide, 
selegiline, linezolid) + an antidepressant 
(particularly a SSRI) 
PD Serotonin syndrome 
- Concurrent use is contraindicated  
- Wait at least 14 days between stopping a MAO inhibitor and starting another antidepressant; 
wait at least 7 to 14 days between stopping another antidepressant and starting a MAO 
inhibitor (5 weeks with fluoxetine) 
- Monitor patients for signs of serotonin syndrome (hypertension, tachycardia, hyperthermia, 
myoclonus, mental status changes) 




effect of verapamil, 
diltiazem, macrolide 
- Closely monitor serum levels of carbamazepine and adjust the dosage accordingly 
- Advise patients to promptly report any signs of carbamazepine toxicity such as headache, 
nausea, vomiting, dizziness, confusion, slurred speech, nystagmus, visual disturbances, tremors 
and ataxia  
- DDI-48: Reduce carbamazepine dosage by one-half upon initiation of verapamil or diltiazem. 
Monitor blood pressure and cardiac effect after initiating carbamazepine 
- DDI-49: Substitute with a non-macrolide antibiotic therapy or wait at least two weeks of 
discontinuing carbamazepine before using a macrolide. If co-administered, monitor patients for 
antimicrobial efficacy 
DDI-49 
carbamazepine + some macrolides (i.e. 
erythromycin or clarithromycin or 
roxithromycin or telithromycin) 
PK 
DDI-50 
acetylcholinesterase inhibitor + a drug that 
reduces heart rate (i.e. antiarrhythmic 
drugs or beta-blockers or  verapamil or 
diltiazem) 
PD Bradycardia 
- Use with caution, particularly in patients with increased risk of developing cardiac conduction 
disturbances  
- Advise patients to promptly report any symptoms such as dizziness, light-headedness, fainting 
or irregular heartbeat 
DDI-51 theophylline + cimetidine PK 
Theophylline toxicity 
- Closely monitor the theophylline serum levels and adjust the dosage accordingly  
- Advise patients to promptly report any signs of theophylline toxicity such as nausea, vomiting, 
diarrhoea, headache, seizures, restlessness, insomnia, or irregular heartbeat/palpitations 
- DDI-54: Substitute with other SSRI or reduce the theophylline dosage by one-third and closely 
monitor serum theophylline levels  
DDI-52 theophylline + a quinolone PK 
DDI-53 
theophylline + some macrolides (i.e. 
erythromycin or clarithromycin or 
roxithromycin or telithromycin) 
PK 
DDI-54 theophylline + fluvoxamine PK 
DDI-55 
thiopurines (e.g. azathioprine) + 
allopurinol 
PK Azathioprine toxicity 
- Reduce the azathioprine dosage by one-quarter to one-third  
- Closely monitor patients for hematologic toxicity (leukopenia, thrombocytopenia, anaemia)  
- Advise patients to report any signs of thiopurine toxicity such as fever, chills, sore throat, 
fatigue, lethargy, pallor, anorexia, jaundice, dark urine, nausea, vomiting, signs of local infection 
and unusual bleeding or bruising 




NSAID ulceration or bleeding - Advise patients to report any signs of gastrointestinal ulceration and bleeding such as severe 
abdominal pain, dizziness, light-headedness and the appearance of black, tarry stools 
DDI-57 






- Minimise the number of anticholinergic drugs and consider non-anticholinergic alternatives  
- Closely monitor patients for additive anticholinergic effects such as mydriasis, blurred vision, 
flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, 
constipation, memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, 
hyperactivity, twitching or jerking movements, stereotypy and seizures  
- Advise patients to promptly report any potential signs of anticholinergic effects such as 
abdominal pain, fever, heat intolerance, blurred vision, confusion or hallucinations 
DDI-58 ciclosporin + rifampicin PK Organ rejection 
- Monitor serum levels of the immunosuppressant and adjust the dosage accordingly  
- Monitor patient for signs of organ rejection 
DDI-59 
ergot alkaloid (e.g. ergotamine)  + some 
macrolides (i.e. erythromycin or 
clarithromycin or roxithromycin or 
telithromycin) 
PK Ergot toxicity  
- Concurrent use is contraindicated given the potential for ergot toxicity characterised by nausea, 
vomiting, peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension 
DDI-60 methotrexate + trimethoprim PD + PK 
Potentially fatal 
methotrexate toxicity  
- Closely monitor patients for hematologic toxicity (e.g. myelosuppression, pancytopenia, 
megaloblastic anaemic, severe bone marrow depression)  
- Advise patients to promptly report any signs and symptoms of bone marrow depression or 
anaemia such as fever, chills, sore throat, easy bruising or bleeding, pallor, dizziness, fatigue, 
lethargy, sore mouth or tongue and tingling in hands or feet 
DDI-61 





- Concomitant use is contraindicated  
- The time after when nitrates can be safely administered following PDE5 inhibitors use is 
uncertain and could go as far as 48 hours. Even then, closely monitor patients for hemodynamic 
response 
DDI-62 tamoxifen + vitamin K antagonist Unknown Bleeding 
- Concomitant use is contraindicated  
- Consider using lower doses of vitamin K antagonist and closely monitor the INR  
DDI-63 tamoxifen + citalopram or escitalopram PD 
Ventricular 
arrhythmias, torsade 
de pointes and sudden 
death 
- Closely monitor patients for ECG changes  
- Advise patients to promptly report any signs of toxicity such as drowsiness, dizziness, 
fainting/syncope, confusion or palpitations 
DDI-64 





- Consider other antidepressant with a limited impact in CYP2D6 activity or, eventually, 
aromatase inhibitors as tamoxifen substitutes 
DDI-65 
concomitant prescription of ≥ 2 drugs that 
reduce potassium (e.g. 2-agonists, 




torsade de pointes 
- Closely monitor serum potassium levels  
- Advise patients to promptly report any signs of hypokalaemia such as fatigue, weakness, 
myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and 
irregular heartbeat. 




- Closely monitor patients’ sodium levels, blood pressure and pulse  
- Advise patient to avoid rising abruptly from a sitting or recumbent position and to promptly 






ACE: angiotensin-converting enzyme; ARB: angiotensin II type 1 receptor blockers; CNS: central nervous system; CrCl: creatinine clearance; CYP: cytochrome P450; DDI: drug-drug interaction; ECG: electrocardiogram; H2: 
histamine-2-receptor; INR: International Normalised Ratio; MAO: Monoamine oxidase; NSAID: non-steroidal anti-inflammatory drug; OATP: organic anion transporting polypeptide; PD: pharmacodynamic; PDE5: 
phosphodiesterase type 5;  PK: pharmacokinetic; P-gp: P-glycoprotein; PPI: proton pump inhibitor; SmPC: Summary of product characteristics; SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake 
inhibitor 
* For key principles to guide optimal use of the DDI list by clinicians, please refer to Table 3. 
† Additional data on the mechanism of interaction are provided In Appendix 5. Pharmacodynamic DDIs occur between drugs with additive or opposing effects. They can be anticipated based on knowledge of the clinical effects of 
the drugs involved (mode of action, organs affected in relation to action or side effects). Pharmacokinetic DDIs cannot be predicted from the clinical effects of the drugs involved. They require knowledge on the PK parameters 
(absorption, distribution, metabolism and elimination) of each drug, and these parameters may vary between drugs of the same pharmacological class. 






Table 3. Key principles to guide optimal use of the DDI list (table 2) by clinicians 
- DDIs are potentially clinically significant, not definitely clinically significant 
- The DDI list is not intended to identify all potential DDIs in a given patient, but rather to 
call attention to drug combinations that are commonly problematic in older adults.  
- The DDI list should be a starting point for a comprehensive process of identifying DDIs and 
improving safety 
- Read the suggestions for management in the DDI table. They will help to identify some 
factors that may increase the risks for specific patients 
- For fully detailed information on the evidence and management of these DDIs, use specific 
and recognised DDI resources 
- The explicit nature of the DDI list allows for easy implementation in clinical decision support 
systems, but does not replace more comprehensive electronic systems detecting an 






Appendix 1. Flowchart of participants and DDI pairs in the Delphi study 
 
Abbreviations: DDI: drug-drug interaction; HCP: healthcare professionals 
* DDI pair with a median score of ≥4 and P25 ≥3 were directly included in the final list of DDIs 
† DDIs with a median score of <3 were directly excluded  
‡ Merging and splitting-up DDI pairs was also performed for the 28 DDIs directly included in rounds 1 and 2, resulting in 23 
DDI pairs 




Appendix 2a: Median [P25-P75] scores obtained for thedrug-drug interactions pairs evaluated in 
Delphi Round I (n=74) 
Drug-drug interaction pairs 
Median 
score 
P25 P75  Decision 
Digoxin + amiodarone 4 3 4 Included 
Digoxin + verapamil 4 3 4 Included 
Digoxin + diltiazem 3,5 3 4 Round 2 
Digoxin + propafenone 3 3 4 Round 2 
Digoxin + quinidine 3,5 3 4 Round 2 
Digoxin + macrolides 3 3 4 Round 2 
Digoxin + thiazide diuretic 3 2 3 Round 2 
Vitamin K antagonist + fibrate 3 2 3,5 Round 2 
Vitamin K antagonist + cimetidine 3 2 3,25 Round 2 
Vitamin K antagonist + metronidazole 3 2 3 Round 2 
Vitamin K antagonist + amiodarone 3 3 3 Round 2 
Oral anticoagulant (i.e. vitamin K antagonist or factor 
Xa inhibitor or direct thrombin inhibitor) + oral NSAID 
4 3 4 Included 
Oral anticoagulant (i.e. vitamin K antagonist or factor 
Xa inhibitor or direct thrombin inhibitor) +  antiplatelet 
drug (including aspirin) 
4 3 4 Included 
Vitamin K antagonist + trimethoprim/sulfamethoxazole 3 3 4 Round 2 
Vitamin K antagonist + quinolone 3 2 3 Round 2 
Vitamin K antagonist + macrolide 3 3 4 Round 2 
Vitamin K antagonist + thyroid hormone 2 2 3 Excluded 
Vitamin K antagonist + SSRI 2,5 2 3 Excluded 
Vitamin K antagonist + SNRI (i.e. venlafaxine, 
duloxetine) 
2 2 3 Excluded 
Dabigatran/edoxaban + P-gp inhibitor (ketoconazole, 
itraconazole, verapamil, quinidine, dronedarone,  
amiodarone, ciclosporin, clarithromycin, erythromycin, 
ritonavir) 
4 3 4 Included 
Rivaroxaban/apixaban + P-gp inhibitor or a CYP3A4-
inhibitor (ketoconazole, itraconazole, voriconazole, 
posaconazole, fluconazole, diltiazem, verapamil, 
quinidine, dronedarone, amiodarone, ciclosporin, 
ritonavir, clarithromycin, erythromycin) 
4 3 4 Included 
Oral NSAID + antiplatelet drug (including aspirin) 3 3 4 Round 2 
Clopidogrel + PPIs ((es)omeprazole, rabeprazole, 
lansoprazole) 
2 2 3 Excluded 
Concomitant use of ≥ 2 potassium-conserving drugs 
(i.e. amiloride, triamterene, eplerenone, 
spironolactone, ACE inhibitors, ARBs, NSAIDs, 
trimethoprim/sulfamethoxazole) 
3,5 3 5 Round 2 
ACE inhibitor / ARB + potassium supplement 3 3 4 Round 2 
Potassium-sparing diuretic + potassium supplement 3 3 4 Round 2 
ACE inhibitor / ARB + oral NSAID 3 3 3 Round 2 
Antihypertensive + oral NSAID 3 2 3 Round 2 
Oral NSAID + diuretic 3 3 3 Round 2 
Statin, all + gemfibrozil 3 2,75 4 Round 2 
Atorvastatin / simvastatin / lovastatin + verapamil or 
diltiazem 
3 2 3 Round 2 




Atorvastatin / simvastatin / lovastatin + erythromycin/ 
clarithromycin / roxithromycin / telithromycin 
3 3 4 Round 2 
Statin + azithromycin 2 2 3 Excluded  
Calcium channel blocker + CYP3A4 inhibitor 3 3 4 Round 2 
Disopyramide + some macrolides (i.e. erythromycin, 
clarithromycin, telithromycin) 
4 3 5 Included 
Beta-blocker + verapamil or diltiazem 4 3 4 Included 
Procainamide + amiodarone 4 3 5 Included 
Procainamide + trimethoprim 3 3 4 Round 2 
Furosemide + etacrynic acid 3 2 4 Round 2 
Concomitant use of ≥ 3 centrally-acting drugs (i.e. 
opiates or antipsychotics or benzodiazepines/z-drugs 
or barbiturates or antiepileptics or antidepressants or 
anti-dementia drugs or psychostimulants) 
4 3 4 Included 
Alprazolam or diazepam or midazolam or triazolam or 
zolpidem or zopiclone + a CYP3A4 inhibitor 
3 2 4 Round 2 
Tricyclic antidepressant + clonidine 3 2 3 Round 2 
SSRI + metoclopramide 3 2 4 Round 2 
SSRI + another serotoninergic drug (including 
tramadol) 
3 3 3 Round 2 
SSRI + MAO inhibitors (i.e. selegiline, rasagiline, 
safinamide phenelzine, moclobemide) 
4 3,75 4 Included 
Oral NSAID + SSRI 3 2,75 4 Round 2 
Oral NSAID + SNRI  3 2 3 Round 2 
Fluoxetine + tricyclic antidepressant 4 3 4 Included 
Lithium + (oral) NSAID 3 3 4 Round  2 
Lithium + a diuretic 4 3 4 Included 
Lithium + ACE inhibitor or ARB  3 3 4 Round 2 
MAO inhibitor (i.e. phenelzine, moclobemide, 
rasagiline, safinamide, selegiline, linezolid) + a 
sympathomimetic drug 
4 3 4 Included 
MAO-A inhibitor  (i.e. moclobemide) or a non-selective 
MAO inhibitor (i.e. phenelzine or linezolid) + levodopa 
4 3 4 Included 
MAO inhibitor (i.e. phenelzine, moclobemide, 
rasagiline, safinamide, selegiline, linezolid) + some 
opiates (i.e. meperidine or fentanyl or oxycodone) 
4 3 4 Included 
MAO inhibitors (i.e. Rasagiline, safinamide, selegiline, 
phenelzine, moclobemide) + antidepressants (e.g. 
trazodone, SSRI, SNRI, tricyclic antidepressant) 
4 3 4 Included 
Phenytoin + omeprazole 2 2 3 Excluded 
Carbamazepine + verapamil 3 2 3,25 Round 2 
Carbamazepine + diltiazem 3 2 4 Round 2 
Carbamazepine + some macrolides (i.e. erythromycin 
or clarithromycin or roxithromycin or telithromycin) 
3 2,75 4 Round 2 
Acetylcholinesterase inhibitor + a drug that reduces 
heart rate (i.e. antiarrhythmic drugs or beta-blockers 
or  verapamil or diltiazem) 
3 2,75 3 Round 2 
Theophylline + cimetidine 3 3 4 Round 2 
Theophylline + quinolone 3 3 4 Round 2 
Theophylline + some macrolides (i.e. erythromycin or 
clarithromycin or roxithromycin or telithromycin) 
3 3 4 Round 2 
Theophylline + fluvoxamine 3 3 4 Round 2 
Thiopurines (e.g. azathioprine) + allopurinol 4 3 5 Included 




Concomitant prescription of ≥ 2 anticholinergic drugs 3 3 4 Round 2 
Tamoxifen + fluoxetine 4 3 4 Included 
Tamoxifen + paroxetine 4 2,75 4 Round 2 
Cyclosporine + rifampicin 4 4 5 Included 
Ergot alkaloid + erythromycin, clarithromycin, 
roxithromycin, telithromycin 
4 3 4 Included 
Methotrexate + trimethoprim 4 4 4,25 Included 
Phosphodiesterase type-5 inhibitors (e.g. sildenafil, 
tadalafil, vardenafil) + daily nitrate therapy for angina 
4 3 4 Included 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II type 1 receptor blockers; CYP, cytochrome P450; 
MAO, Monoamine oxidase; NSAID, non-steroidal anti-inflammatory drug; P-gp, P-glycoprotein; PPI, proton pump inhibitor; 





Appendix 2b: Median [P25-P75] scores obtained for the drug-drug interactions pairs evaluated in Delphi Round II (n=53) 
Drug-drug interaction pairs 
Median 
score 
P25 P75  Decision 
Digoxin + verapamil or diltiazem 4 3 4 Included 
Digoxin + propafenone 3 3 4 Consensus meeting 
Digoxin + quinidine 4 3 4 Included 
Digoxin + some macrolides (i.e. erythromycin or 
clarithromycin or azithromycin or roxithromycin or 
telithromycin) 
3 3 3,5 Consensus meeting 
Digoxin + thiazide diuretic 3 3 3 Consensus meeting 
Vitamin K antagonist + fibrate 3 3 3 Consensus meeting 
Vitamin K antagonist + cimetidine 3 3 3 Consensus meeting 
Vitamin K antagonist + metronidazole 3 3 3 Consensus meeting 
Vitamin K antagonist + amiodarone 3 3 3,5 Consensus meeting 
Vitamin K antagonist + trimethoprim/sulfamethoxazole 3 3 4 Consensus meeting 
Vitamin K antagonist + quinolone 3 3 3 Consensus meeting 
Vitamin K antagonist + macrolide 3 3 3 Consensus meeting 
Oral NSAID + antiplatelet drug (including aspirin) 3 3 4 Consensus meeting 
Concomitant use of ≥ 2 potassium-conserving drugs 
(i.e. amiloride, triamterene, eplerenone, 
spironolactone, ACE inhibitors, ARBs, NSAIDs, 
trimethoprim/sulfamethoxazole) 
4 4 4,5 Included 
ACE inhibitor / ARB + potassium supplement 3 3 4 Consensus meeting 
Potassium-sparing diuretic + potassium supplement 3 3 4 Consensus meeting 
ACE inhibitor / ARB + oral NSAID 3 3 3 Consensus meeting 
Antihypertensive + oral NSAID 3 3 3 Consensus meeting 
Oral NSAID + diuretic 3 3 3 Consensus meeting 
Statin, all + gemfibrozil 3 3 4 Consensus meeting 
Atorvastatin / simvastatin / lovastatin + verapamil or 
diltiazem 
3 3 3 Consensus meeting 
Atorvastatin / simvastatin / lovastatin + amiodarone 3 3 3 Consensus meeting 
Atorvastatin / simvastatin / lovastatin + erythromycin / 
clarithromycin / roxithromycin / telithromycin 
3 3 3 Consensus meeting 
Calcium channel blocker + CYP3A4 inhibitor 3 3 3,5 Consensus meeting 
Procainamide + trimethoprim 3 3 4 Consensus meeting 
Furosemide + ethacrynic acid 3 3 4 Consensus meeting 
Alprazolam or diazepam or midazolam or triazolam or 
zolpidem or zopiclone + a CYP3A4 inhibitor 
3 3 3,5 Consensus meeting 
Tricyclic antidepressant + clonidine 3 2 3 Consensus meeting 
SSRI + metoclopramide 3 3 3,75 Consensus meeting 
SSRI + another serotoninergic drug (including 
tramadol) 
3 3 3 Consensus meeting 
Oral NSAID + SSRI 3 3 3 Consensus meeting 
Oral NSAID + SNRI  3 3 3 Consensus meeting 
Lithium + (oral) NSAID 3 3 4 Consensus meeting 
Lithium + ACE inhibitor or ARB 3 3 4 Consensus meeting 
Carbamazepine + verapamil 3 3 3 Consensus meeting 
Carbamazepine + diltiazem 3 3 3 Consensus meeting 
Carbamazepine + some macrolides (i.e. erythromycin 
or clarithromycin or roxithromycin or telithromycin) 




Acetylcholinesterase inhibitor + a drug that reduces 
heart rate (i.e. antiarrhythmic drugs or beta-blockers 
or  verapamil or diltiazem) 
3 3 3 Consensus meeting 
Theophylline + cimetidine 3 3 3,5 Consensus meeting 
Theophylline + quinolone 3 3 4 Consensus meeting 
Theophylline + some macrolides (i.e. erythromycin or 
clarithromycin or roxithromycin or telithromycin) 
3 3 4 Consensus meeting 
Theophylline + fluvoxamine 3 3 4 Consensus meeting 
Oral or parenteral corticosteroids + oral NSAIDs  3 3 3,5 Consensus meeting 
Concomitant prescription of ≥ 2 anticholinergic drugs 3 3 3 Consensus meeting 
Tamoxifen + paroxetine / fluoxetine / sertraline 4 3,5 4 Included 
Digoxin + loop diuretica 3 3 4 Consensus meeting 
Tamoxifen + warfarina 3 3 4 Consensus meeting 
Tamoxifen + (es)citaloprama 3 3 3,5 Consensus meeting 
Tamoxifen + bupropiona 4 3 4 Included 
Simvastatin + amlodipinea 3 2 3 Consensus meeting 
Salbutamol + drugs that reduce potassium (e.g. loop or 
thiazide diuretics) a 
3 2 3 Consensus meeting 
SSRI + loop or thiazide diureticsa 3 3 4 Consensus meeting 
Acetylcholinesterase inhibitor + anticholinergic druga 2 2 3 Excluded 
Abbreviations: ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blockers; NSAID, 
non-steroidal anti-inflammatory drug; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin 
reuptake inhibitor 







Appendix 3. Answers of participants (N=24) for the drug-drug interaction pairs evaluated at final round 
 
Drug-drug interaction pairs (median score of 3 at round 2) N 
 
% Decision* 
digoxin + propafenone 18 75 Included  
digoxin + some macrolides (i.e. erythromycin or clarithromycin or 
azithromycin or roxithromycin or telithromycin) 23 96 Included 
digoxin + thiazide or loop diuretic 19 79 Included 
vitamin K antagonist + a fibrate 22 92 Included 
vitamin K antagonist + cimetidine 18 75 Included 
vitamin K antagonist + metronidazole 22 92 Included 
vitamin K antagonist + amiodarone 23 96 Included 
vitamin K antagonist + trimethoprim/sulfamethoxazole 22 92 Included 
vitamin K antagonist + a quinolone 20 83 Included 
vitamin K antagonist + a macrolide 21 88 Included 
antiplatelet drug (including aspirin) + oral NSAID  21 88 Included 
ACE inhibitor or ARB or a potassium-sparing diuretic + a potassium 
supplement 22 92 Included 
ACE inhibitor or ARB + an oral NSAID  20 83 Included 
antihypertensive + oral NSAID  14 58 Excluded 
diuretic + oral NSAID 19 79 Included 
statin  + gemfibrozil 24 100 Included 
atorvastatin or simvastatin or lovastatin + verapamil or diltiazem 22 92 Included 
simvastatin + amlodipine 19 79 Included 
atorvastatin or simvastatin or lovastatin + amiodarone 23 96 Included 
atorvastatin or simvastatin or lovastatin + some macrolides (i.e. erythromycin 
or clarithromycin or roxithromycin or telithromycin) 22 92 Included 
calcium channel blocker + a CYP3A4 inhibitor 20 83 Included 
procainamide + trimethoprim 21 88 Included 
furosemide + etacrynic acid 19 79 Included 
alprazolam or diazepam or midazolam or triazolam or zolpidem or zopiclone 
+ a CYP3A4 inhibitor  18 75 Included 
tricyclic antidepressant + clonidine 14 58 Excluded 
SSRI + metoclopramide  17 71 Excluded 
SSRI + another serotonergic drug (including tramadol)  22 92 Included 
oral NSAID + SSRI or SNRIs 19 79 Included 
lithium +  NSAID 24 100 Included 
lithium + ACE inhibitor or an ARB 23 96 Included 
carbamazepine + verapamil or  diltiazem 20 83 Included 
carbamazepine + some macrolides (i.e. erythromycin or clarithromycin or 
roxithromycin or telithromycin) 20 83 Included 
acetylcholinesterase inhibitor + a drug that reduces heart rate (i.e. 
antiarrhythmic drugs or beta-blockers or  verapamil or diltiazem) 20 83 Included 
theophylline + cimetidine 20 83 Included 
theophylline + a quinolone 22 92 Included 
theophylline + some macrolides (i.e. erythromycin or clarithromycin or 
roxithromycin or telithromycin) 22 92 Included 
theophylline + fluvoxamine 23 96 Included 




concomitant prescription of ≥ 2 anticholinergic drugs 22 92 Included 
tamoxifen + vitamin K antagonist 21 88 Included 
tamoxifen + citalopram or escitalopram 20 83 Included 
concomitant prescription of ≥ 2 drugs that reduce potassium  19 79 Included 
SSRI + loop or thiazide diuretic 19 79 Included 
Abbreviations: ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blockers; NSAID, 
non-steroidal anti-inflammatory drug; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin 
reuptake inhibitor 








Appendix  4. Drug-drug interaction pairs excluded from the final list 
- Vitamin K antagonist + thyroid hormone 
- Vitamin K antagonist + SSRI 
- Vitamin K antagonist + SNRI (i.e. venlafaxine, duloxetine) 
- Clopidogrel + PPIs ((es)omeprazole, rabeprazole, lansoprazole) 
- Statin + azithromycin 
- Phenytoin + omeprazole 
- Acetylcholinesterase inhibitor + anticholinergic drugs 
- Antihypertensive + oral NSAID 
- Tricyclic antidepressant + clonidine  
- SSRI + metoclopramide 
Abbreviations: NSAID, non-steroidal anti-inflammatory drug; PPI: proton pump inhibitor; SNRI: 






Appendix 5. Final list of potentially clinically significant drug-drug interactions in older people (n=66)* 
DDI-
number 
Drug-drug interaction pairs 
Type of 
interaction† 
Mechanism of interaction Potential harm Management 
DDI-1 digoxin + amiodarone PK + PD 
- Increased digoxin exposure 
due to the inhibition of P-gp 
by amiodarone 
- Additive bradycardia 
Digoxin toxicity, that may 
lead to potentially fatal 
cardiac arrhythmia 
- Reduce the digoxin dosage by one-third to one-half  
- Monitor serum digoxin levels closely and adjust dosage 
accordingly 
- Advise patients to promptly report any signs of digoxin 
toxicity such as nausea, vomiting, anorexia, visual 
disturbances, slow pulse/bradycardia, or irregular 
heartbeat/arrhythmia  
DDI-2 digoxin + verapamil or diltiazem PK + PD 
- Decreased digoxin clearance 
possibly relying, at least in the 
case of verapamil, on P-gp 
inhibition 
- Additive effects in slowing 
atrioventricular node 
conduction 
Digoxin toxicity, that may 
lead to potentially fatal 
cardiac arrhythmia 
- Reduce the digoxin dosage by one-third to one-half 
- Monitor serum digoxin levels closely and adjust dosage 
accordingly 
- Advise patients to promptly report any signs of digoxin 
toxicity such as nausea, vomiting, anorexia, visual 
disturbances, slow pulse/bradycardia, or irregular 
heartbeat/arrhythmia.  
DDI-3 digoxin + propafenone  Unknown 
Not fully understood 
Propafenone may increase serum 
digoxin concentration 
Digoxin toxicity, that may 
lead to potentially fatal 
cardiac arrhythmia 
- Monitor serum digoxin levels closely and adjust dosage 
accordingly 
- Advise patients to promptly report any signs of digoxin 
toxicity such as nausea, vomiting, anorexia, visual 
disturbances, slow pulse/bradycardia, or irregular 
heartbeat/arrhythmia  
DDI-4 digoxin + quinidine PK 
Increased digoxin exposure, 
possibly relying on P-gp inhibition 
by quinidine 
Digoxin toxicity, that may 
lead to potentially fatal 
cardiac arrhythmia 
- Reduce the digoxin dosage by one-half 
- Monitor serum digoxin levels closely and adjust dosage 
accordingly 
- Advise patients to promptly report any signs of digoxin 
toxicity such as nausea, vomiting, anorexia, visual 
disturbances, slow pulse/bradycardia, or irregular 
heartbeat/cardiac arrhythmias  
DDI-5 
digoxin + some macrolides (i.e. 
erythromycin or clarithromycin 
or azithromycin or 
roxithromycin or telithromycin) 
PK 
Increased digoxin exposure due 
to the inhibition of P-gp by some 
macrolides 
Digoxin toxicity, that may 
lead to potentially fatal 
cardiac arrhythmia 
- Substitute with non-macrolide antibiotic or reduce 
digoxin dosage by one-third to one-half 
- Monitor serum digoxin levels closely and adjust dosage 
accordingly 
- Advise patients to promptly report any signs of digoxin 
toxicity such as nausea, vomiting, anorexia, visual 
disturbances, slow pulse/bradycardia, or irregular 
heartbeat/cardiac arrhythmias 
DDI-6 
digoxin + thiazide or loop 
diuretic 
PD 
Potentiation of cardiac glycoside-
mediated Na-K-ATPase inhibition 
Digoxin toxicity,                                
that may lead to 





due to the induction of 
hypokalaemia and 
hypomagnesaemia by diuretics 
potentially fatal cardiac 
arrhythmia 
- Advise patients to promptly report any signs of digoxin 
toxicity or electrolyte disturbances such as weakness, 
lethargy, muscle pains or cramps,  nausea, anorexia, 
visual changes, slow pulse/bradycardia, or irregular 
heartbeat/cardiac arrhythmias  
DDI-7 vitamin K antagonist + a fibrate PK + PD 
Not fully understood 
- Protein binding displacement 
of vitamin K antagonists by 
fibrates 
- Additive effects on 
anticoagulation 
Bleeding 
- Reduce the vitamin K antagonist dosage by one-third to 
one-half 
- Monitor the INR closely and adjust the vitamin K 
antagonist dosage accordingly 
- Advise patients to report any signs of excessive 
anticoagulation such as unusual or prolonged bleeding, 
bruising, vomiting, change in stool or urine colour, 
headache, dizziness or weakness 
DDI-8 
vitamin K antagonist + 
cimetidine 
PK 
Increased vitamin K antagonist 
exposure due to the inhibition of 
CYP1A2- and CYP2C19-mediated 
metabolisms by cimetidine 
Bleeding 
- Substitute with a non-interacting gastroprotective drug 
(e.g. PPI like pantoprazole or another H2 antagonist) 
- Monitor the INR closely and adjust the vitamin K 
antagonist dosage accordingly 
- Advise patients to report any signs of excessive 
anticoagulation such as unusual or prolonged bleeding, 
bruising, vomiting, change in stool or urine colour, 
headache, dizziness or weakness 
DDI-9 
vitamin K antagonist + 
metronidazole 
PK 
Increased vitamin K antagonist 
exposure due to the inhibition 
CYP2C9-mediated metabolism by 
metronidazole 
Bleeding 
- Monitor the INR closely and adjust the vitamin K 
antagonist dosage accordingly 
- Advise patients to report any signs of excessive 
anticoagulation such as unusual or prolonged bleeding, 
bruising, vomiting, change in stool or urine colour, 
headache, dizziness or weakness 
DDI-10 
vitamin K antagonist + 
amiodarone 
PK 
Increased vitamin K antagonist 
exposure due to the inhibition of 
CYP1A2-, CYP2C9-, CYP3A4-
mediated metabolism by 
amiodarone 
Bleeding 
- Reduce the vitamin K antagonist dosage by one-quarter 
to one-half  
- Monitor the INR closely and adjust the vitamin K 
antagonist dosage accordingly 
- Advise patients to report any signs of excessive 
anticoagulation such as unusual or prolonged bleeding, 
bruising, vomiting, change in stool or urine colour, 
headache, dizziness or weakness 
DDI-11 
oral anticoagulant (i.e. vitamin K 
antagonist or factor Xa inhibitor 
or direct thrombin inhibitor) + 
an oral NSAID 
PD 
Potentiation of the bleeding risk 
associated with oral 
anticoagulants due to additive 
pharmacodynamic effects on 
haemostasis and gastrointestinal 
Bleeding, gastrointestinal 
bleeding and toxicity (i.e. 
inflammation, ulceration 
and perforation) 
- Consider the addition of a PPI or H2 antagonist during 
treatment with NSAID 
- Advise patients to promptly report any signs of 
excessive anticoagulation such as unusual or prolonged 




irritation or ucleration by NSAIDs colour, headache, dizziness or weakness 
DDI-12 
oral anticoagulant (i.e. vitamin K 
antagonist or factor Xa inhibitor 
or direct thrombin inhibitor) + 
an antiplatelet drug (including 
aspirin) 
PD Additive effects on haemostasis Bleeding 
- Advise patients to promptly report any signs of 
excessive anticoagulation such as unusual or prolonged 
bleeding, bruising, vomiting, change in stool or urine 
colour, headache, dizziness or weakness   
DDI-13 
vitamin K antagonist + 
trimethoprim/sulfamethoxazole 
PK + PD 
- Increased vitamin K 
antagonist exposure due to 
the inhibition of CYP2C9-
mediated metabolism by 
sulfamethoxazole 
- Potentiation of the 
hypothrombinaemic effect of 
vitamin K antagonist through 
the disruption of vitamin K-




- Substitute with another antibiotic 
- Monitor the INR closely and adjust the vitamin K 
antagonist dosage accordingly 
- Advise patients to promptly report any signs of 
excessive anticoagulation such as unusual or prolonged 
bleeding, bruising, vomiting, change in stool or urine 
colour, headache, dizziness or weakness 
DDI-14 
vitamin K antagonist + a 
quinolone 
Unknown 
Not fully understood 
Potentiation of the 
hypothrombinaemic effect of 
vitamin K antagonist through the 
disruption of vitamin K-producing 
intestinal flora by quinolones 
Bleeding 
- Monitor the INR closely and adjust the vitamin K 
antagonist dosage accordingly 
- Advise patients to promptly report any signs of 
excessive anticoagulation such as unusual or prolonged 
bleeding, bruising, vomiting, change in stool or urine 
colour, headache, dizziness or weakness  
DDI-15 
vitamin K antagonist + a 
macrolide 
PK + PD 
Not fully understood 
- Potentiation of the 
hypothrombinaemic effect of 
vitamin K antagonist through 
the disruption of vitamin K-
producing intestinal flora by 
macrolides 
- Increased vitamin K 
antagonist exposure due to 
the inhibition of CYP3A4-
mediated metabolism by 
macrolides 
Bleeding 
- Monitor the INR closely and adjust the vitamin K 
antagonist dosage accordingly 
- Advise patients to promptly report any signs of 
excessive anticoagulation such as unusual or prolonged 
bleeding, bruising, vomiting, change in stool or urine 
colour, headache, dizziness or weakness  
DDI-16 
dabigatran + a P-gp inhibitor 
(ketoconazole, itraconazole, 
verapamil, quinidine,  
amiodarone, dronedarone, 
PK 
Increased exposure to dabigatran 
due to the inhibition of P-gp-
mediated efflux transport 
Bleeding 
- Not recommended with ketoconazole, itraconazole, 
ciclosporin, dronedarone, ritonavir. For other 







- Specific recommendations for management may differ 
depending on: presence of risk factors (including renal 
failure), indication, interacting drug. Refer to 
appropriate literature and SmPC. 
- Advise patients to promptly report any signs of 
excessive anticoagulation such as unusual or 
prolonged bleeding, bruising, vomiting, change in stool 
or urine colour, headache, dizziness or weakness 
DDI-17 







Increased exposure to edoxaban 
due to the inhibition of P-gp-
mediated efflux transport 
Bleeding 
- Reduce dosage or use with caution. Specific 
recommendations for management may differ 
depending on: presence of risk factors, indication, 
interacting drug. Refer to appropriate literature and 
SmPC. 
- Advise patients to promptly report any signs of 
excessive anticoagulation such as unusual or 
prolonged bleeding, bruising, vomiting, change in stool 
or urine colour, headache, dizziness or weakness   
DDI-18 







ciclosporin, , clarithromycin, 
erythromycin, ritonavir) 
PK 
Increased exposure to 
rivaroxaban due to the inhibition 
of P-gp and CYP3A4-mediated 
metabolism 
Bleeding 
- Not recommended with azoles, ritonavir, 
dronedarone. For other interacting drugs, avoid use or 
use with caution 
- Specific recommendations for management may differ 
depending on: presence of risk factors (including renal 
failure), indication, interacting drug. Refer to 
appropriate literature and SmPC. 
- Advise patients to promptly report any signs of 
excessive anticoagulation such as unusual or 
prolonged bleeding, bruising, vomiting, change in stool 
or urine colour, headache, dizziness or weakness 
DDI-19 









Increased exposure to apixaban 
due to the inhibition of P-gp and 
CYP3A4-mediated metabolism 
Bleeding 
- Not recommended with azoles, ritonavir. For other 
interacting drugs, avoid use, reduce dosage and/or use 
with caution 
- Specific recommendations for management may differ 
depending on: presence of risk factors (including renal 
failure), indication, interacting drug. Refer to 
appropriate literature and SmPC. 
- Advise patients to promptly report any signs of 
excessive anticoagulation such as unusual or prolonged 
bleeding, bruising, vomiting, change in stool or urine 
colour, headache, dizziness or weakness 
DDI-20 
antiplatelet drug (including 
aspirin) + oral NSAID  
PD 
- Potentiation of bleeding risk 
associated with oral 
 
- Bleeding, 





anticoagulants due to 
additive pharmacodynamic 
effects on haemostasis and 
gastrointestinal irritation by 
NSAIDs 
- Competition at the platelet 
cyclooxygenase-1 (COX-1) 
binding site between aspirin 
and other NSAIDs 
gastrointestinal 




With aspirin, decreased 
cardioprotective effect 
- Advise patients to promptly report any signs of 
ulceration and bleeding such as abdominal pain, 
bloating, sudden dizziness or light-headedness, nausea, 
vomiting, hematemesis, anorexia, and melena 
- In order to preserve the cardioprotective effect of low-
dose aspirin, administer the latter at least 2 hours 
before or at least 8h after NSAID intake 
DDI-21 
concomitant use of ≥ 2 
potassium-sparing drugs (i.e. 
amiloride, triamterene, 
eplerenone, spironolactone, ACE 
inhibitors, ARBs, NSAIDs, 
trimethoprim/sulfamethoxazole) 
PD 
Additive effects resulting in 
potassium retention 
Hyperkalaemia 
- Extra caution is required in patients with moderate 
renal impairment, diabetes, severe or worsening heart 
failure, dehydration, or concomitant therapy with other 
agents that increase serum potassium such as beta-
blockers, ciclosporine, heparin, tacrolimus, and 
trimethoprim. Avoid concurrent use in patients with 
severe renal impairment (CrCl < 30 ml/min) 
- Closely monitor patients for serum potassium levels 
and renal function 
- Educate patients about the potential danger of 
excessive potassium in the diet and advise them to 
promptly report any signs of hyperkalaemia such as 
nausea, vomiting, weakness, listlessness, tingling of the 
extremities, paralysis, confusion, weak pulse, and a 
slow or irregular heartbeat 
DDI-22 
ACE inhibitor or ARB or a 
potassium-sparing diuretic + a 
potassium supplement 
PD 
Additive effects resulting in 
potassium retention 
Hyperkalaemia 
- Closely monitor serum potassium levels 
- Educate patients about the potential danger of 
excessive potassium in the diet and advise them to 
promptly report any signs of hyperkalaemia such as 
nausea, vomiting, weakness, listlessness, tingling of the 
extremities, paralysis, confusion, weak pulse, and a 
slow or irregular heartbeat 
DDI-23 
ACE inhibitor or ARB + an oral 
NSAID  
PD 
- Additive adverse effects on 
renal function 
- Antagonist effects on blood 
pressure  
- Deterioration of renal 
function and 
hyperkalaemia 
Altered blood pressure 
control   
- Keep the use of NSAIDs to a minimum in patients on 
antihypertensives, especially in those with blood 
pressures that are relatively high, as well as in those 
with high salt intake 
- Monitor patient for altered blood pressure control and 
for renal function 
- Ensure adequate hydration, avoiding dehydration or 
fluid overload 
DDI-24 diuretic + oral NSAID PD 
- Additive adverse effects on 
renal function 
- Deterioration of renal 
function, 
- Keep the use of NSAID to a minimum in patients taking 




- Antagonist effects on 





Altered blood pressure 
control 
are relatively high, as well as in those with high salt 
intake or with congestive heart failure 
- Monitor patients for signs of worsening renal function 
and assure diuretic efficacy, including appropriate 
effects on blood pressure 
- Ensure adequate hydration, avoiding dehydration or 
fluid overload 
DDI-25 statin  + gemfibrozil PK 
Increased statin exposure due to 
gemfibrozil-mediated inhibition 
of the glucuronidation process 
and of the OATP1B1 transporter 
Severe myopathy and 
rhabdomyolysis which may 
lead to acute renal failure 
and death 
- Contraindicated in a number of conditions considered 
to be risk factors for myopathy (i.e. renal impairment, 
hypothyroidism) 
- Reduce the statin dosage to the lowest effective dose 
and consider using a fibrate other than gemfibrozil. If 
maintained, gemfibrozil dosage should not exceed 
10mg daily 
- Discontinue statin therapy if creatine kinase is 
markedly elevated in the absence of strenuous exercise 
or if myopathy is otherwise suspected or diagnosed 
- Advise patients to promptly report any unexplained 
muscle pain, tenderness or weakness, particularly if 
accompanied by fever, malaise and/or dark-coloured 
urine 
DDI-26 
atorvastatin or simvastatin or 
lovastatin + verapamil or 
diltiazem 
PK 
Increased statin exposure due to 
the inhibition of CYP3A4-
mediated metabolism by 
verapamil and diltiazem 
Severe myopathy and 
rhabdomyolysis which may 
lead to acute renal failure 
and death 
- Consider safer alternatives not metabolized by CYP3A4 
(e.g. fluvastatin, pravastatin or rosuvastatin) 
- Reduce the dosage of involved statins to the lowest 
effective dose 
- Discontinue statin if creatine kinase is markedly 
elevated in the absence of strenuous exercise or if 
myopathy is otherwise suspected or diagnosed 
- Advise patients to promptly report any unexplained 
muscle pain, tenderness or weakness, particularly if 
accompanied by fever, malaise and/or dark-coloured 
urine 
DDI-27 simvastatin + amlodipine PK 
Not fully understood  
Substrate competition for 
CYP3A4-mediated metabolism  
Severe myopathy and 
rhabdomyolysis which may 
lead to acute renal failure 
and death 
- Consider safer alternatives not metabolized by CYP3A4 
(e.g. fluvastatin, pravastatin or rosuvastatin) 
- Reduce the statin dosage to the lowest effective dose 
and do not exceed 20mg simvastatin daily 
- Discontinue statin if creatine kinase is markedly 
elevated in the absence of strenuous exercise or if 
myopathy is otherwise suspected or diagnosed 
- Advise patients to promptly report any unexplained 




accompanied by fever, malaise and/or dark-coloured 
urine 
DDI-28 
atorvastatin or simvastatin or 
lovastatin + amiodarone 
PK 
Increased statin exposure due to 
the inhibition of CYP3A4-
mediated metabolism by 
amiodarone 
Severe myopathy and 
rhabdomyolysis which may 
lead to acute renal failure 
- Consider safer alternatives not metabolised by CYP3A4 
(e.g. fluvastatin, pravastatin, rosuvastatin) 
- Reduce the statin dosage to the lowest effective dose 
(not exceeding 20mg simvastatin and 40mg lovastatin 
daily) 
- Discontinue statin if creatine kinase is markedly 
elevated in the absence of strenuous exercise or if 
myopathy is otherwise suspected or diagnosed 
- Advise patients to promptly report any unexplained 
muscle pain, tenderness or weakness, particularly if 
accompanied by fever, malaise and/or dark-coloured 
urine 
DDI-29 
atorvastatin or simvastatin or 
lovastatin + some macrolides 
(i.e. erythromycin or 
clarithromycin or roxithromycin 
or telithromycin) 
PK 
Some macrolides inhibit CYP3A4-
mediated metabolism, resulting 
in increased statin exposure 
Severe myopathy and 
rhabdomyolysis which may 
lead to acute renal failure 
- Substitute with a non-interacting antibiotic or 
temporarily withdraw the statin as long as macrolide 
antibiotics are required, except if benefits outweigh 
risks 
- Reduce the statin dosage to the lowest effective dose 
- Discontinue statin if creatine kinase is markedly 
elevated in the absence of strenuous exercise or if 
myopathy is otherwise suspected or diagnosed 
- Advise patients to promptly report any unexplained 
muscle pain, tenderness or weakness, particularly if 
accompanied by fever, malaise and/or dark-coloured 
urine 
DDI-30 
calcium channel blocker + a 
CYP3A4 inhibitor (ketoconazole, 
itraconazole, voriconazole, 
posaconazole, fluconazole, 





Increased exposure to calcium 
channel blockers due the 
inhibition of CYP3A4-mediated 
metabolism 
Increased effects of 
calcium channel blockers  
- Monitor patients for cardiotoxicity (e.g. QT 
prolongation, torsade de pointes, bradycardia, 
congestive heart failure) 
- Advise patients to promptly report any increased 
effects of calcium channels blockers such as headache, 
flushing, excessive hypotension, reflex tachycardia, 
oedema, difficulties breathing, chest pain or tightness  
DDI-31 
disopyramide + some 
macrolides (i.e. erythromycin, 
clarithromycin telithromycin) 
PK + PD 
- Increased disopyramide 
exposure due to the 
inhibition of CYP3A4-
mediated metabolism 
- Additive effects on QT 
prolongation 
Hypoglycaemic coma, QT 
prolongation, torsade de 
pointes, heart block and 
ventricular fibrillation 
- Avoid concurrent use except if benefits outweigh risks 
- Substitute with non-macrolide antibiotic 
- Closely monitor patients for cardiotoxicity 
- Advise patients to promptly report any symptoms that 
could indicate the occurrence of torsade de pointes 
such as dizziness, light-headedness, fainting, 






beta-blocker + verapamil or 
diltiazem 
PD 
Additive cardiac depressant 
effects with reduction in heart 
rate, atrioventricular conduction 




congestive heart failure, 
severe hypotension, 
exacerbation of angina, 
ventricular asystole, sinus 
arrest, heart block 
- Generally avoid concurrent use, particularly in patients 
predisposed to heart failure 
- Closely monitor patient hemodynamic response and 
tolerance and adjust the dosage of one or both agents 
accordingly 
- Advise patients to promptly report any symptoms 
including fatigue, headache, fainting, swelling of the 
extremities, weight gain, shortness of breath, chest 
pain, increased or decreased heartbeat, or irregular 
heartbeat 
DDI-33 procainamide + amiodarone PD 
Additive depressant effects on 
cardiac conduction 
(Exacerbation of pre-
existing) arrhythmias and 
QT prolongation 
- Avoid concurrent use except for patients with life-
threatening ventricular arrhythmias who are 
incompletely responsive to a single agent or to 
amiodarone alone 
- Reduce the dosage of both agents by one-third to one-
half 
- Monitor patients for conduction disturbances and 
exacerbation of tachyarrhythmia 
- Advise patients to promptly report any symptoms that 
could indicate the occurrence of torsade de pointes 
such as dizziness, light-headedness, fainting, 
palpitations, irregular heartbeat, shortness of breath, 
or syncope. 
DDI-34 procainamide + trimethoprim PK 
Increased procainamide exposure 
due to competition for active 
tubular excretion with 
trimethoprim 
Cardiac adverse effects 
including QT prolongation, 
torsade de pointes, cardiac 
arrest 
- Reduce the procainamide dosage. Monitor serum 
procainamide levels as well as patient response and 
adjust the procainamide dosage accordingly 
- Patients should be advised to promptly report any signs 
of procainamide toxicity including drowsiness, 
dizziness, syncope, confusion, tremor or palpitations 
DDI-35 furosemide + etacrynic acid PD 
Additive or synergistic ototoxic 
effects 
Ototoxicity with risk of 
tinnitus, reversible or 
irreversible hearing 
impairment, deafness 
- Avoid concurrent use 
DDI-36 
concomitant use of  ≥ 3 
centrally-acting drugs (i.e. 
opiates or antipsychotics or 
benzodiazepines/z-drugs or 
barbiturates or  antiepileptics or 
antidepressants) 
PD 
Additive depressant effect on 
central nervous system 
Increased risk of falls and 
fracture, impaired 
cognition 
- Minimise the number of CNS agents 
- Limit the dosage and duration of each drug to the 
minimum possible while achieving the desired clinical 
effect 





alprazolam or diazepam or 
midazolam or triazolam or 
zolpidem or zopiclone + a 
CYP3A4 inhibitor (ketoconazole, 
itraconazole, voriconazole, 
posaconazole, fluconazole, 





Increased exposure to 
benzodiazepine and z-drugs due 
to the inhibition of CYP3A4-
mediated metabolism 
Excessive sedation and 
prolonged hypnotic effects 
- Consider benzodiazepine/Z-drug dosage reduction 
- Advise patients to promptly report any symptoms of 
nausea, vomiting, diarrhoea, confusion, daytime 
sedation, dizziness or unconsciousness 
DDI-38 
SSRI + another serotonergic drug 





- Additive serotonergic actions  
- With tramadol :  
i) both drugs lower seizure 
threshold and  
inhibition of CYP2D6-mediated 
conversion of tramadol into its 
active O-demethylated 
metabolite by SSRIs 
- Serotonin syndrome  
With tramadol: seizures 
and diminished 
therapeutic response to 
tramadol 
- Closely monitor for symptoms of the serotonin 
syndrome such as hypertension, tachycardia, 
hyperthermia, myoclonus, mental status changes, 
particularly when initiating or increasing dosages of 
these agents. Consider potential risk even when 
administering serotonergic agents sequentially, as 
some of them may demonstrate prolonged elimination 
half-life (e.g. fluoxetine)  
- With tramadol, use with caution regarding increased 
risk of seizure and monitor patient’s therapeutic 
response  
- When discontinuing a serotonergic CYP2D6 inhibitor in 
a patient receiving tramadol therapy, consider a 
tramadol dose reduction and monitor for signs of 
respiratory depression or sedation 
DDI-39 oral NSAID + SSRI or SNRIs PD 
NSAID potentiation of bleeding 
risk associated with 
antidepressants (additive effects 
on platelet inhibition, 
gastrointestinal irritation)  
Bleeding, gastrointestinal 
bleeding 
- Substitute with alternatives to NSAIDs (e.g. 
paracetamol) or less gastrotoxic NSAIDs (e.g. 
ibuprofen) 
- Consider the addition of gastroprotective drugs (e.g. 
PPI, H2 antagonists) 
- Advise patients to promptly report any signs of 
excessive anticoagulation such as unusual or prolonged 
bleeding, bruising, vomiting, change in stool or urine 
colour, headache, dizziness or weakness  
DDI-40 
fluoxetine + tricyclic 
antidepressant 
PD + PK 
- Additive serotonergic effects  
- Additive effects on QT 
prolongation  
- Increased exposure to 
tricyclic antidepressant due to 
the inhibition of CYP2D6-
mediated metabolism by 
- Serotonergic syndrome  
Tricyclic antidepressant 
toxicity, including cardiac 
arrhythmias  
- Consider tricyclic antidepressant dosage reduction and 
serum level monitoring, even several weeks after 
fluoxetine discontinuation  
- Closely monitor patients for signs of tricyclic 
antidepressants toxicity (e.g.  cardiac arrhythmias, 
sedation, dry mouth, blurred vision, constipation, 




fluoxetine  activity (e.g. CNS irritability, altered consciousness, 
confusion, myoclonus, ataxia, abdominal cramping, 
hyperpyrexia, shivering, pupillary dilation, diaphoresis, 
hypertension, and tachycardia)  
- If serotonin syndrome occurs, immediately discontinue 
fluoxetine and tricyclic antidepressants  
- If ventricular arrhythmias develop, consider fluoxetine 
discontinuation and cardiac evaluation  
DDI-41 lithium +  NSAID PK 
Decreased lithium renal excretion 
due to NSAID inhibition of renal 
prostaglandin synthesis and thus 
reduction of renal blood flow 
Lithium toxicity, potentially 
life-threatening  
- Extra caution is advised in a number of conditions 
including advanced age, impaired renal function, 
decreased sodium intake, volume depletion, renal 
artery stenosis, and heart failure as these increase the 
risk of toxicity. 
- Reduce the lithium dosage, titrate slowly and 
frequently monitor serum concentrations  
- Closely monitor patients for signs of lithium toxicity 
including drowsiness, dizziness, confusion, weakness, 
ataxia, tremor, tinnitus, blurred vision, nystagmus, 
vomiting, diarrhoea, thirst, diabetes insipidus (polyuria, 
polydipsia), seizure and ECG changes  
- Advise patients to promptly report any signs of lithium 
toxicity (listed above)  
DDI-42 lithium + diuretic PK 
Not fully understood 
Decreased lithium excretion due 
to compensatory distal 
reabsorption of sodium and 
lithium salt upon sodium loss 
induced by diuretics.  
Lithium toxicity, potentially 
life-threatening  
- Extra caution is advised in a number of conditions 
including advanced age, impaired renal function, 
decreased sodium intake, volume depletion, renal 
artery stenosis and heart failure  
- Reduce the lithium dosage, titrate slowly, and 
frequently monitor serum concentrations  
- Closely monitor patients for signs of lithium toxicity 
including drowsiness, dizziness, confusion, weakness, 
ataxia, tremor, tinnitus, blurred vision, nystagmus, 
vomiting, diarrhoea, thirst, diabetes insipidus (polyuria, 
polydipsia), seizure and ECG changes  
- Advise patients to promptly report any signs of lithium 
toxicity (listed above)  
DDI-43 lithium + ACE inhibitor or an ARB PK 
Not fully understood 
Decreased lithium excretion due 
to compensatory distal 
reabsorption of sodium and 
lithium salt upon sodium loss 
induced by ACE inhibitors and 
Lithium toxicity, potentially 
life-threatening  
- Extra-caution is advised in a number of conditions 
including advanced age, impaired renal function, 
decreased sodium intake, volume depletion, renal 
artery stenosis and heart failure  
- Reduce the lithium dosage, titrate slowly, and 




ARBs - Closely monitor patients for signs of lithium toxicity 
including drowsiness, dizziness, confusion, weakness, 
ataxia, tremor, tinnitus, blurred vision, nystagmus, 
vomiting, diarrhoea, thirst, diabetes insipidus (polyuria, 
polydipsia), seizure, ECG changes  
- Advise patients to promptly report any signs of lithium 
toxicity (listed above) 
DDI-44 
MAO inhibitor (i.e. phenelzine, 
moclobemide, rasagiline, 
safinamide, selegiline, linezolid) 
+ sympathomimetic 
PD 
Excessive adrenergic response 
due to the inhibition of 
noradrenaline degradation by 
MAO inhibitors and potentiated 
by the action of 
sympathomimetics 
Hypertensive crisis 
- Concurrent use is contraindicated  
- Wait at least 14 days after MAO inhibitor 
discontinuation before starting sympathomimetic use 
DDI-45 
MAO-A inhibitor  (i.e. 
moclobemide) or non-selective 
MAO inhibitor (i.e. phenelzine or 
linezolid) + levodopa 
PD 
Additive effects resulting in 
increased levels of dopamine and 
noradrenaline 
Hypertensive crisis 
- Avoid concurrent use even if carbidopa or benserazide 
are given in combination with levodopa 
- Wait two to three weeks after MAO-A inhibitor 
discontinuation before starting levodopa treatment 
DDI-46 
MAO inhibitor (i.e. phenelzine, 
moclobemide, rasagiline, 
safinamide, selegiline, linezolid) 
+ some opioids (i.e. meperidine 
or fentanyl) 
PD 
Not fully understood  
- Excessive serotonergic 
response  
- Potentiation of CNS effect of 
opioids by MAO inhibitors 
- Serotonin syndrome  
Respiratory depression, 
cyanosis, hypotension and 
coma 
- Concurrent use is contraindicated or not 
recommended  
- Wait at least 14 days after MAO inhibitor 
discontinuation before starting an opioid 
DDI-47 
MAO inhibitor (i.e. phenelzine, 
moclobemide, rasagiline, 
safinamide, selegiline, linezolid) 
+ an antidepressant (particularly 
a SSRI) 
PD Additive serotonergic effects Serotonin syndrome 
- Concurrent use is contraindicated  
- Wait at least 14 days between stopping a MAO 
inhibitor and starting another antidepressant; wait at 
least 7 to 14 days between stopping another 
antidepressant and starting a MAO inhibitor (5 weeks 
with fluoxetine) 
- Monitor patients for signs of serotonin syndrome 
(hypertension, tachycardia, hyperthermia, myoclonus, 
mental status changes) 
DDI-48 
carbamazepine + verapamil or  
diltiazem 
PK 
- Increased carbamazepine 
exposure due to the 
inhibition of CYP3A4-
mediated metabolism by 
verapamil and diltiazem  
- Decreased exposure to 
verapamil and diltiazem due 
to the induction of CYP3A4-
mediated metabolism by 
- Carbamazepine toxicity  
Decreased therapeutic 
effect of verapamil and 
diltiazem 
- Closely monitor serum levels of carbamazepine when 
initiating or discontinuing verapamil or diltiazem  
- Reduce carbamazepine dosage by one-half upon 
initiation of verapamil or diltiazem  
- Advise patients to promptly report any signs of 
carbamazepine toxicity such as headache, nausea, 
vomiting, dizziness, confusion, slurred speech, 
nystagmus, visual disturbances, tremors and ataxia  




carbamazepine initiating carbamazepine 
DDI-49 
carbamazepine + some 
macrolides (i.e. erythromycin or 
clarithromycin or roxithromycin 
or telithromycin) 
PK 
- Increased carbamazepine 
exposure due to the 
inhibition of CYP3A4-
mediated metabolism (and P-
gp) by some macrolides  
- Decreased macrolide 




- Carbamazepine toxicity  
Decreased macrolide 
efficacy 
- Closely monitor serum levels of carbamazepine and 
adjust the dosage accordingly  
- Advise patients to promptly report any signs of 
carbamazepine toxicity such as headache, nausea, 
vomiting, dizziness, confusion, slurred speech, 
nystagmus, visual disturbances, tremors and ataxia  
- Substitute with a non-macrolide antibiotic therapy or 
wait at least two weeks of discontinuing 
carbamazepine before using a macrolide. If co-
administered, monitor patients for antimicrobial 
efficacy 
DDI-50 
acetylcholinesterase inhibitor + 
a drug that reduces heart rate 
(i.e. antiarrhythmic drugs or 
beta-blockers or  verapamil or 
diltiazem) 
PD Additive bradycardia Bradycardia 
- Use with caution, particularly in patients with increased 
risk of developing cardiac conduction disturbances  
- Advise patients to promptly report any symptoms such 
as dizziness, light-headedness, fainting or irregular 
heartbeat 
DDI-51 theophylline + cimetidine PK 
Increased theophylline exposure 
due to CYP1A2-mediated 
metabolism by cimetidine 
Theophylline toxicity 
- Closely monitor the theophylline serum levels and 
adjust the dosage accordingly  
- Advise patients to promptly report any signs of 
theophylline toxicity such as nausea, vomiting, 
diarrhoea, headache, seizures, restlessness, insomnia, 
or irregular heartbeat/palpitations 
DDI-52 theophylline + a quinolone PK 
Increased theophylline exposure 
due to the inhibition of CYP1A2-
mediated metabolism 
Theophylline toxicity 
- Closely monitor theophylline serum levels and adjust 
the dosage accordingly  
- Advise patients to promptly report any  signs of 
theophylline toxicity such as nausea, vomiting, 
diarrhoea, headache, seizures, restlessness, insomnia, 
or irregular heartbeat/palpitations 
DDI-53 
theophylline + some macrolides 
(i.e. erythromycin or 
clarithromycin or roxithromycin 
or telithromycin) 
PK 
Increased theophylline exposure 
due to the inhibition of CYP3A4-
mediated metabolism by some 
macrolides 
Theophylline toxicity  
- Closely monitor theophylline serum levels and adjust 
the dosage accordingly  
- Advise patients to promptly report any  signs of 
theophylline toxicity such as nausea, vomiting, 
diarrhoea, headache, seizures, restlessness, insomnia, 
or irregular heartbeat/palpitations 
DDI-54 theophylline + fluvoxamine PK 
Increased theophylline exposure 
due to the inhibition of CYP1A2-
mediated metabolism by 
fluvoxamine 
Theophylline toxicity 
- Substitute with other SSRI or reduce the theophylline 
dosage by one-third and closely monitor serum 
theophylline levels  
- Advise patients to report any signs of theophylline 




headache, tremor, irritability, confusion, insomnia, 
seizure, palpitations and arrhythmia 
DDI-55 
thiopurines (e.g. azathioprine) + 
allopurinol 
PK 
Increased exposure to the active 
metabolite of azathioprine 
(mercaptopurine) due to xanthine 
oxidase inhibition by allopurinol   
Azathioprine toxicity 
- Reduce the azathioprine dosage by one-quarter to one-
third  
- Closely monitor patients for hematologic toxicity 
(leukopenia, thrombocytopenia, anaemia)  
- Advise patients to report any signs of thiopurine 
toxicity such as fever, chills, sore throat, fatigue, 
lethargy, pallor, anorexia, jaundice, dark urine, nausea, 
vomiting, signs of local infection and unusual bleeding 
or bruising 
DDI-56 
oral or parenteral corticosteroid 
+ an oral NSAID 
PD 




- Consider the addition of gastroprotective drugs (e.g. 
PPI, H2 antagonists)  
- Advise patients to report any signs of gastrointestinal 
ulceration and bleeding such as severe abdominal pain, 
dizziness, light-headedness and the appearance of 
black, tarry stools 
DDI-57 
concomitant prescription of ≥ 2 
anticholinergic drugs 
PD Additive anticholinergic effects 
Anticholinergic effects 
including cognitive decline 
- Minimise the number of anticholinergic drugs and 
consider non-anticholinergic alternatives  
- Closely monitor patients for additive anticholinergic 
effects such as mydriasis, blurred vision, flushed face, 
fever, dry skin and mucous membranes, tachycardia, 
urinary retention, constipation, memory loss, 
disorientation, incoherence, hallucinations, psychosis, 
delirium, hyperactivity, twitching or jerking 
movements, stereotypy and seizures  
- Advise patients to promptly report any potential signs 
of anticholinergic effects such as abdominal pain, fever, 
heat intolerance, blurred vision, confusion or 
hallucinations 
DDI-58 ciclosporin + rifampicin PK 
Decreased exposure to 
immunosuppressants due to the 
induction of both CYP3A4-
mediated metabolism and P-gp 
by rifampicin  
Organ rejection 
- Monitor serum levels of the immunosuppressant and 
adjust the dosage accordingly  
- Monitor patient for signs of organ rejection 
DDI-59 
ergot alkaloid (e.g. ergotamine)  
+ some macrolides (i.e. 
erythromycin or clarithromycin 
or roxithromycin or 
telithromycin) 
PK 
Increased exposure to ergot 
derivatives due to the inhibition 
of CYP3A4-mediated metabolism 
by some macrolides 
Ergot toxicity  
- Concurrent use is contraindicated given the potential 
for ergot toxicity characterised by nausea, vomiting, 
peripheral vasospasm, ischemia, thrombosis, 




DDI-60 methotrexate + trimethoprim PD + PK 
Not fully understood  
- Additive effects on 
dihydrofolate reductase 
inhibition  
- Increased exposure to 
methotrexate due to protein 
binding displacement and 
reduced tubular excretion 
Potentially fatal 
methotrexate toxicity  
- Closely monitor patients for hematologic toxicity (e.g. 
myelosuppression, pancytopenia, megaloblastic 
anaemic, severe bone marrow depression)  
- Advise patients to promptly report any signs and 
symptoms of bone marrow depression or anaemia such 
as fever, chills, sore throat, easy bruising or bleeding, 
pallor, dizziness, fatigue, lethargy, sore mouth or 
tongue and tingling in hands or feet 
DDI-61 
phosphodiesterase type 5-
inhibitor + nitrate 
PD 
Additive effects on cGMP 
accumulation resulting in 




- Concomitant use is contraindicated  
- The time after when nitrates can be safely 
administered following PDE5 inhibitors use is uncertain 
and could go as far as 48 hours. Even then, closely 
monitor patients for hemodynamic response 
DDI-62 
tamoxifen + vitamin K 
antagonist 
Unknown Not understood Bleeding 
- Concomitant use is contraindicated  
- Consider using lower doses of vitamin K antagonist and 
closely monitor the INR  
DDI-63 
tamoxifen + citalopram or 
escitalopram 
PD 
Additive effects on QT 
prolongation 
Ventricular arrhythmias, 
torsade de pointes and 
sudden death 
- Closely monitor patients for ECG changes  
- Advise patients to promptly report any signs of toxicity 
such as drowsiness, dizziness, fainting/syncope, 
confusion or palpitations 
DDI-64 
tamoxifen + paroxetine or  
fluoxetine or bupropion 
PK 
Decreased exposure to tamoxifen 
active metabolite due to the 
inhibition of CYP2D6-mediated 
metabolism by antidepressants  
Reduced effectiveness of 
tamoxifen 
- Consider other antidepressant with a limited impact in 
CYP2D6 activity or, eventually, aromatase inhibitors as 
tamoxifen substitutes 
DDI-65 
concomitant prescription of ≥ 2 
drugs that reduce potassium 
(e.g. 2-agonists, thiazides, loop 
diuretics, corticosteroids)  
PD Additive hypokalaemia 
Hypokalaemia, QT 
prolongation and torsade 
de pointes 
- Closely monitor serum potassium levels  
- Advise patients to promptly report any signs of 
hypokalaemia such as fatigue, weakness, myalgia, 
muscle cramps, numbness, tingling, abdominal pain, 
constipation, palpitation, and irregular heartbeat. 
DDI-66 SSRI + loop or thiazide diuretic PD Additive hyponatraemia 
Hyponatraemia, 
orthostatic hypotension  
- Closely monitor patients’ sodium levels, blood pressure 
and pulse  
- Advise patient to avoid rising abruptly from a sitting or 
recumbent position and to promptly report any signs of 
hyponatraemia including nausea, vomiting, headache, 
confusion, lethargy, weakness 
ACE: angiotensin-converting enzyme; ARB: angiotensin II type 1 receptor blockers; CNS: central nervous system; CrCl: creatinine clearance; CYP: cytochrome P450; DDI: drug-drug interaction; ECG: 
electrocardiogram; H2: histamine-2-receptor; INR: International Normalised Ratio; MAO: Monoamine oxidase; NSAID: non-steroidal anti-inflammatory drug; OATP: organic anion transporting polypeptide; PD: 
pharmacodynamic; PDE5: phosphodiesterase type 5;  PK: pharmacokinetic; P-gp: P-glycoprotein; PPI: proton pump inhibitor; SmPC: Summary of product characteristics; SNRI: serotonin-norepinephrine 




* For key principles to guide optimal use of the DDI list by clinicians, please refer to Table 3. 
† Pharmacodynamic DDIs occur between drugs with additive or opposing effects. They can be anticipated based on knowledge of the  clinical effects of the drugs involved (mode of action, organs affected in 
relation to action or side effects). Pharmacokinetic DDIs cannot be predicted from the clinical effects of the drugs involved. They require knowledge on the PK parameters (absorpt ion, distribution, 






Appendix 6: Summary of the DDI list, per medication class (A), and per type of adverse event and medication class (B) 
 




Calcium channel blockers 









Trimethoprim + sulfamethoxazole 
Quinolones 
Central nervous system 
Combination: ≥3 centrally-active drugs 
MAO-inhibitor 








Abbreviations: ACE: angiotensin-converting enzyme; ARB: angiotensin II type 1 receptor blockers; CNS: Central Nervous 
System ; DOAC: Direct oral anticoagulant ; MAO: Monoamine oxydase; NSAID: non-steroidal anti-inflammatory drug; SNRI: 




B. Drug-drug interactions classified by type of adverse event and by medication class 
  Cardiovascular Coagulation Infections CNS Other 
Bleeding  
amiodarone (10) VKA (7-15;62) metronidazole (9) SSRI; SNRI (39) PgP/CYP3A4 inhibitors (16-19) 























Diuretic (24)       NSAID (24) 
beta-blocker (32) 
   
  
verapamil, diltiazem(32)         
Heart block disopyramide (31)   macrolide (31)     
  beta-blocker (32) 
   
  
  verapamil, diltiazem (32) 
   
  
QT prolongation, 
torsade de pointe 
disopyramide (31)   macrolide (31) (es)citalopram (63) Drugs that reduce potassium (65) 





amiodarone (34)         




PgP/CYP3A4 inhibitors (30) 
antiarrythmic (50) 
   
  
beta-blocker (32; 50) 
   
  





digoxin (1;2;3;4;5;6)   macrolide (5)     
quinidine (4) 
   
  
amiodarone (1) 
   
  
verapamil, diltiazem (2) 
   
  
thiazide, loop diuretics (6) 
   
  
propafenone (3)         
Blood pressure control  




   
MAO-inhibitor (44;45) sympathomimetic (44) 
  Diuretic (25) 
  
levodopa (45)   
  
 
        
Hypotension Nitrate (61)       phosphodiesterase type 5 inhibitor 
(61) 
Electrolytes disturbances 
Hyperkalemia Diuretic (21;22;24)   trimethoprim-
sulfamet (21) 
  NSAID (21;23;24) 
  ACEI, ARBs (21-23) 
   
Potassium supplement (22) 
Hypokalemia         ≥2 drugs that reduce potassium (65) 
Hyponatremia loop, thiazide diuretic (66) 
  
SSRI (66)   
Deterioration of 
renal function 
ACEI, ARB (23)       NSAID (23;24) 
  Diuretic (24)         
CNS toxicity 
Impaired cognition, 
falls and fracture, 
excessive sedation 
      Benzodiazepine/Z-
drug (36;37) 
CYP3A4 inhibitors (37) 





cognitive decline  
        ≥2 anticholinergic drugs (57) 
Serotonin syndrome       SSRI (38; 40; 47) 
 
   
tricyclic 
antidepressant (40) 
serotoninergic drug (48) 
   
tramadol (38)      
Opioid (46)      
MAO inhibitor (46)   
      antidepressant (47)   
Specific drug toxicity  
Lithium toxicity 
  
Diuretic (42)     Lithium (41-43) NSAID (41) 
ACEI, ARB (43)         
Carbamazepine 
toxicity 
verapamil, diltiazem (48)   macrolide (49) carbamazepine 
(48;49) 
  
Theophylline toxicity     macrolide (53) fluvoxamine (54) theophylline (51-54) 
    quinolone (52)   cimetidine (51) 
Azathioprine toxicity         Thiopurine (55) 
        allopurinol (55) 
Ergot toxicity     macrolide (59) ergot alkaloid (59)   
Methotrexate 
toxicity 




        ≥2 anticholinergic drugs (60) 
Myopathy/ 
rhabdomyolysis 
Statin (25-29)   macrolide (29)     
gemfibrozil (25) 
   
  
diltiazem, verapamil (26) 
   
  
amlodipine (27) 
   
  
amiodarone (28) 
   
  
Organ rejection     rifampicin (58)   cyclosporine (58) 
Ototoxicity furosemide (35)         
etacrinic acid (35)         
Tamoxifen reduced 
effectiveness 
      paroxetine, fluoxetine, 
bupropion (64) 
tamoxifen (64) 
Legend: Blue cells refer to pharmacodynamic drug interactions; orange cells refer to pharmacokinetic interactions (light orange: drug affecting; 
dark orange: drug affected); orange cells with blue text refer to drugs interactions that are both pharmacokinetic and pharmacodynamic by 




interaction (see Table 3). 
Abbreviations: ACE: angiotensin-converting enzyme; ARB: angiotensin II type 1 receptor blockers; CNS: Central Nervous System ; DOAC: Direct 
oral anticoagulant; GI: Gastro-Intestinal; MAO: Monoamine oxidase; NSAID: non-steroidal anti-inflammatory drug; SNRI: serotonin-
norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; VKA: Vitamin K Antagonist 
 
 
